

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 6, 2004, 08:32:42 ; Search time 52 Seconds  
(without alignments)

48.902 Million cell updates/sec

Title: US-09-458-302B-193

Perfect score: 41

Sequence: 1 IMIGVLGV 9

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_29Jan04.\*

1: Geneseqp1980s.\*

2: Geneseqp1990s.\*

3: Geneseqp2000s.\*

4: Geneseqp2001s.\*

5: Geneseqp2002s.\*

6: Geneseqp2003as.\*

7: Geneseqp2003bs.\*

8: Geneseqp2004s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	41	100.0	9	2 AAW70048	CEA deriv
2	41	100.0	9	2 AAY47657	Immuno
3	41	100.0	9	4 AAB99695	HLA A2 bi
4	41	100.0	9	4 AAG62397	Immuno
5	41	100.0	9	5 AAU95888	Immuno
6	41	100.0	9	6 AAE35579	Human CAE
7	41	100.0	9	6 ABU04842	Human exp
8	41	100.0	9	6 ABU04846	Human exp
9	41	100.0	9	6 ABU03347	Human exp
10	41	100.0	9	6 ABU04844	Human exp
11	41	100.0	9	6 ABG74919	melanoma -
12	41	100.0	9	7 ADD84718	Human car
13	41	100.0	10	2 AAW70047	CEA deriv
14	41	100.0	10	2 AAW70051	CEA deriv
15	41	100.0	10	2 AAY47672	Immuno
16	41	100.0	10	2 AAY47668	Immuno
17	41	100.0	10	5 AAU95892	Immuno
18	41	100.0	10	5 AAU95889	Immuno
19	41	100.0	10	6 ABU04847	Human exp
20	41	100.0	10	6 ABU04845	Human exp
21	41	100.0	10	6 ABU04848	Human exp
22	41	100.0	10	6 ABU04843	Human exp
23	41	100.0	12	6 AAE35583	Human CAE
24	41	100.0	12	6 AAE35585	Human CAE
25	41	100.0	12	6 AAE35584	Human CAE



#### ALIGNMENTS

RESULT 1

AAW70048

ID AAW70048 standard; peptide; 9 AA.

XX AC

XX AAW70048;

XX 22-OCT-1998 (first entry)

XX DE CEA derived HLA-A2.1 binding peptide 5 (residues 691-699).

XX KW Cytotoxic T lymphocyte; CTL; major histocompatibility complex; MHC;

XX KW human leukocyte antigen; HLA; tumour associated antigen; cancer;

XX KW antigen presenting cell; APC; immunogenic peptide; immune disorder;

XX KW viral infection; AIDS; hepatitis; bacterial infection; malaria; CEA;

XX KW fungal infection; tuberculosis; melanoma; carcinoembryonic antigen.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO9833888-A1.

XX PD 06-AUG-1998.

XX PF 30-JAN-1998; 98WO-US001959.

XX PR 31-JAN-1997; 97US-0036696P.

XX PA (EPIM-) EPIMMUNE INC.

XX PI Tsai V, Southwood S, Sidney J, Sette A, Celis E;

XX DR WPI; 1998-437445/37.

XX PT Production of antigen-specific cytotoxic T cells - by incubating

XX PT immunogenic peptide(s) from antigen that binds class I major

XX PT histocompatibility complex molecules with pre-treated antigen presenting

XX PS cells.

XX PS Example 6; Page 75; 104pp; English.

XX CC Sequences shown in AAW70044 to AAW70052 represent peptides derived from

XX CC carcinoembryonic antigen (CEA). The peptides can bind to a human

XX CC leukocyte antigen (HLA), HLA-A2.1 and are used to exemplify the method of

XX CC invention of producing antigen-specific cytotoxic T cells (CTLs) in

XX CC vitro. The method comprises contacting immunogenic peptides from an

XX CC antigen that binds class I major histocompatibility complex (MHC)

XX CC molecules with antigen presenting cells (APCs) pretreated with

XX CC pretreatment growth factors, and incubating the APCs with purified CD8

Aae35582 Trypsin d  
Add84716 Human car  
Aae35580 TA compri  
Aae35586 TA compri  
Abu10423 Urokinase  
Aae24334 Human lun  
Abu04802 Human exp  
Aar77435 BGP (1-31  
Aar77435 BGP (1-31  
Aag74097 Human col  
Abu04813 Human exp  
Aau98922 Human car  
Abu04809 Human exp  
Aap81229 Carcinoem  
Aar65168 Carcinoem  
Aaw22844 Human car  
Abu04822 Human exp  
Abu04806 Human exp  
Abu04816 Human exp  
Abu04798 Human exp  
Abu04827 Human exp

26 41 100.0 13 6 AAE35582  
27 41 100.0 16 7 ADD84716  
28 41 100.0 21 6 AAE35580  
29 41 100.0 21 6 AAE35586  
30 41 100.0 29 2 ABU10423  
31 41 100.0 227 5 AAE24334  
32 41 100.0 372 6 ABU04802  
33 41 100.0 493 2 AAR77435  
34 41 100.0 595 4 AAG74097  
35 41 100.0 595 6 ABU04813  
36 41 100.0 670 5 AAU98922  
37 41 100.0 697 6 ABU04809  
38 41 100.0 698 1 AAP81229  
39 41 100.0 698 2 AAR65168  
40 41 100.0 698 2 AAW22844  
41 41 100.0 698 6 ABU04822  
42 41 100.0 698 6 ABU04806  
43 41 100.0 698 6 ABU04816  
44 41 100.0 698 6 ABU04798  
45 41 100.0 698 6 ABU04827

CC cells in the presence of at least 2 incubation growth factors, thereby  
 CC producing antigen-specific CTLs. A method for specifically killing target  
 CC cells in a human patient is also provided which comprises obtaining a  
 CC fluid sample containing CTLs from a patient, contacting the cytotoxic T  
 CC cells with APCs pretreated with pre-treatment growth factors, where the  
 CC APCs comprise class I MHC molecules. The pretreated APCs are incubated  
 CC with the cytotoxic growth factors, thereby producing activated CTLs which  
 CC are contacted with a carrier to form a composition. The composition can  
 CC then be administered to the patient. The activated CTLs can be used for  
 CC treating cancers, immune disorders, viral infections, AIDS, hepatitis,  
 CC bacterial infection, fungal infection, malaria or tuberculosis  
 XX  
 SQ Sequence 9 AA;

Query Match 100.0%; Score 41; DB 2; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
 |||||  
 Db 1 IMIGVLVGV 9

RESULT 2  
 AAY47657  
 ID AAY47657 standard; peptide; 9 AA.

AC AAY47657;

XX 01-DEC-1999 (first entry)

XX Immunogenic peptide having a human leukocyte antigen binding motif #2268.

XX Human leukocyte antigen; binding; immunogenic; glycoprotein; MHC; HLA;  
 KW immune response; T cell activation; major histocompatibility complex;  
 KW cytotoxic T lymphocyte; CTL; tumour rejection; viral infection; cancer;  
 KW prostate cancer; hepatitis B; hepatitis C; AIDS; renal carcinoma;  
 KW vaccine; immunisation.

XX Synthetic.

XX Homo sapiens.

XX WO9945954-A1.

XX 16-SEP-1999.

XX 13-MAR-1998; 98WO-US005039.

XX 13-MAR-1998; 98WO-US005039.

XX (EPIM-) EPIMMUNE INC.

XX Sette A, Kubo RT, Sidney J, Celis E, Grey HM, Southwood S;

XX WPI; 1999-551214/46.

XX New immunogenic peptides with HLA binding motif, useful in treatment and  
 PT diagnosis of cancers and viral diseases.

XX Claim 1; Page 118; 150pp; English.

XX AAY45390 to AAY48214 represent specifically claimed immunogenic peptides  
 CC having a human major histocompatibility complex (MHC) Class I (also known  
 CC as human leukocyte antigen (HLA)) binding motif. The immunogenic peptides  
 CC can bind to a specific HLA allele (i.e. HLA-A subtypes HLA-A2.1, A1, A3.2  
 CC or A24.1 or HLA-B or C) and induce a cytotoxic T cell response against  
 CC the antigen from which the peptide is derived. Cytotoxic T lymphocytes  
 CC (CTLs) which destroy antigen-bearing cells are normally induced by an  
 CC antigen in the form of a peptide fragment bound to a HLA molecule, rather  
 CC than the intact foreign antigen itself, and are particularly important in  
 CC tumour rejection and in fighting viral infections. The peptides are  
 CC therefore useful therapeutically to treat or prevent viral infections and  
 CC cancers in mammals (especially humans) e.g. prostate cancer, hepatitis B

CC and C, AIDS, and renal carcinoma. They can be administered as vaccines to  
 CC elicit an immune response in individuals susceptible or otherwise at risk  
 CC of viral infection or cancer, or used to treat chronic or acute  
 CC conditions. They are also useful diagnostically, and can be used to  
 CC induce a cytotoxic T cell response, by contacting a cytotoxic T cell with  
 CC the peptide e.g. to produce CTLs ex vivo for infusion back into a  
 CC patient. The polynucleotides encoding the immunogenic peptides are also  
 CC useful therapeutically and for immunisation as above  
 XX  
 SQ Sequence 9 AA;

Query Match 100.0%; Score 41; DB 2; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
 |||||  
 Db 1 IMIGVLVGV 9

RESULT 3  
 AAB99695  
 ID AAB99695 standard; peptide; 9 AA.

XX AAB99695;

XX 06-SEP-2001 (first entry)

XX HLA A2 binding CTL epitope peptide from CEA SEQ ID NO:16.

XX Human leukocyte antigen A2 binding peptide; HLA class I A2; CTL;  
 KW cytotoxic T-cell lymphocyte; tumour associated antigen; CEA; HER2/neu;  
 KW MAGE2; MAGE3; p53; vaccine; cancer; cytostatic; immunomodulator;  
 KW immunotherapy; immune response.

XX Homo sapiens.

XX WO200141741-A1.

XX 14-JUN-2001.

XX 13-DEC-2000; 2000WO-US034318.

XX 13-DEC-1999; 99US-0170448P.

XX 05-APR-2000; 2000US-00543608.

XX 30-MAY-2000; 2000US-00583200.

XX (EPIM-) EPIMMUNE INC.

XX Fikes J, Sette A, Sidney J, Southwood S, Celis E, Keogh E;

XX Chesnut R;

XX WPI; 2001-381489/40.

XX Compositions for use in a vaccine for treating, e.g., breast, lung and  
 PT colon cancer comprises at least one peptide that comprises an isolated  
 PT epitope of a tumor-associated antigen.

XX Claim 1; Page 76; 86pp; English.

XX The present invention describes a composition (I) comprising at least one  
 CC peptide that comprises an isolated, prepared epitope consisting of a  
 CC sequence selected from 25 short amino acid sequences given in AAB99680 to  
 CC AAB99704. Also described are: (1) a composition (II) comprising one or  
 CC more peptides, and further comprising at least two epitopes selected from  
 CC the 25 short amino acid sequences (as above), where each of the one or  
 CC more peptides comprise less than 50 contiguous amino acids that have 100%  
 CC identity with a native peptide sequence; and (2) a vaccine composition  
 CC (III) comprising an epitope selected from the 25 short amino acid  
 CC sequences (as above) and a pharmaceutical excipient. (I) has cytostatic  
 CC and immunomodulatory activities and can be used in vaccine production and  
 CC immunotherapy. The peptide epitope compositions (I)-(II) are useful for  
 CC monitoring an immune response to a tumour associated antigen or when one

CC or more peptides are combined to create a vaccine (III) that stimulates  
CC the cellular arm of the immune system. In particular, the vaccine  
CC mediates immune responses against tumours in individuals who bear an  
CC allele of the human leukocyte antigen (HLA)-A2 supertype and improve the  
CC standard of care for patients being treated for breast, colon, or lung  
CC cancer  
XX  
SQ Sequence 9 AA;

Query Match 100.0%; Score 41; DB 4; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
| | | | |  
DB 1 IMIGVLVGV 9

RESULT 4  
AAG62397  
ID AAG62397 standard; peptide; 9 AA.

AC AAG62397;

XX 03-SEP-2001 (first entry)

XX Immunogenic peptide CEA.691 SEQ ID 1.

XX Class I epitope; immunogenic; heteroclitic analogue; immune response;  
XX antigen display; viral disease; cancer.

XX Synthetic.

XX WO200136452-A2.

XX 25-MAY-2001.

XX 20-NOV-2000; 2000WO-US031856.

XX 18-NOV-1999; 99US-0166529P.

XX 06-OCT-2000; 2000US-0239008P.

XX (EPIM-) EPIMMUNE INC.

XX Tangri S, Sette A, Ishioka G;

XX WPI; 2001-355609/37.

XX Enhancing immunogenicity of peptide containing class I epitope, useful  
XX for treating cancer, comprises providing (semi-)conservative amino acid  
XX substitutions at specified positions of these epitopes.

XX Example 1; Fig 1A; 96pp; English.

XX This invention relates to a method of enhancing the immunogenicity of a  
XX peptide, where the peptide contains a class I epitope. The invention  
XX includes methods for preparing peptides containing epitopes which have  
XX enhanced ability to effect an immune response (compared to wild-type  
XX epitopes). The peptides are referred to as heteroclitic analogues. The  
XX method is useful for eliciting an immune response by contacting CTLs with  
XX the immunogenically enhanced peptide in vitro in the presence of an  
XX antigen presenting cell, or by administering to a subject a nucleic acid  
XX molecule comprising a nucleotide sequence encoding the peptide. The  
XX peptides are useful as reagents to evaluate an immune response and the  
XX efficacy of the vaccine, and for making antibodies. The heteroclitic  
XX analogues are useful in immunological compositions for the treatment of  
XX viral diseases, cancer, and other conditions which are characterised by  
XX displayed antigens on target cells. The present sequence represents a  
XX class I epitope which may be used in the method of the invention

XX Sequence 9 AA;

Query Match 100.0%; Score 41; DB 4; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
| | | | |  
DB 1 IMIGVLVGV 9

RESULT 5  
AAU95888  
ID AAU95888 standard; peptide; 9 AA.

XX AAU95888;

XX 02-JUL-2002 (first entry)

XX Immunogenic peptide with (HLA)-A2.1 binding site #101.

XX HLA-A2.1 binding peptide; cytostatic; virucide; anti-HIV; hepatotropic;  
XX human immunodeficiency virus; antiinflammatory; antibacterial; vaccine;  
XX protozoicide; immunosuppressant; immunogenic peptide; T cell activation;  
XX human leukocyte antigen binding site; cytotoxic T cell response;  
XX viral infection; hepatitis; Epstein-Barr virus; papilloma virus;  
XX human immunodeficiency virus; HIV; Kaposi sarcoma; Lassa fever virus;  
XX cytomegalovirus; tumour; prostate cancer; renal carcinoma; lymphoma;  
XX prostate-specific antigen; p53; carcino-embryonal antigen;  
XX melanoma antigen; Mycobacterium tuberculosis; protozoa;  
XX trypanosome surface antigen; condyloma acuminatum.

XX Unidentified.

XX WO200220616-A1.

XX 14-MAR-2002.

XX 01-SEP-2000; 2000WO-US024102.

XX 01-SEP-2000; 2000WO-US024102.

XX (EPIM-) EPIMMUNE INC.

XX Grey HM, Sette A, Sidney J, Southwood S;

XX WPI; 2002-351766/38.

XX Immunogenic peptide with human leukocyte antigen-A2.1 binding site,  
XX useful for treating e.g. viral infection or tumors.

XX Claim 1; Page 27; 35pp; English.

XX The invention describes a composition comprising an immunogenic peptide  
XX having a human leukocyte antigen (HLA)-A2.1 binding site. The peptides  
XX bind specifically to HLA-A2.1, to cause T cell activation and thus a  
XX cytotoxic T cell response. The peptides and the nucleic acids that  
XX encode them, are used, in vivo or ex vivo, for treatment of viral  
XX infections (hepatitis B or C; Epstein-Barr; human immune deficiency;  
XX Kaposi sarcoma; human papilloma; Lassa fever or cytomegaloviruses);  
XX tumours including prostate cancer, renal carcinoma and lymphoma (where  
XX directed to prostate-specific antigen, p53, carcino-embryonal antigen,  
XX Her2/neu or melanoma antigens); infection by Mycobacterium tuberculosis  
XX or protozoa (directed to trypanosome surface antigen); and condyloma  
XX acuminatum. The peptides are suitable for use in peptide-based vaccines.  
XX This sequence represents an immunogenic peptide with the human leukocyte  
XX antigen (HLA)-A2.1 binding site, described in the invention

XX Sequence 9 AA;

Query Match 100.0%; Score 41; DB 5; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
| | | | |

```
Db      1 IMIGVLGV 9

RESULT 6
AAE35579
ID   AAE35579 standard; peptide; 9 AA.
XX
AC   AAE35579;
XX
DT   17-JUN-2003 (first entry)
XX
XX   Human CAE specific HLA-A2-restricted minimal CTL epitope #1.
DE
DE   Fusion agent; immunogenic; proliferative disease; infectious disease;
KW   cancer; therapy; vaccine; melanoma; carcinoembryonic antigen; CAE; TA;
KW   Trojan antigen; human; HLA-A2-restricted CTL epitope.
XX
XX   Homo sapiens.
OS
XX
XX   WO200294994-A2.
PN
XX
XX   28-NOV-2002.
PD
XX
XX   20-MAY-2002; 2002WO-US015992.
PF
XX
XX   18-MAY-2001; 2001US-0291874P.
PR
XX
XX   (MAYO-) MAYO FOUND MEDICAL EDUCATION RES.
PA
XX
XX   Celis E;
PI
XX
XX   WPI; 2003-140367/13.
DR
XX
XX   Fusion agent useful for preventing and treating an infectious disease, or
PT   a proliferative disease, such as cancer, comprises a transport domain,
PT   two cleavage sites, a peptide epitope and a biologically active agent.
XX
XX   Example 2; Page 43; 72pp; English.
XX
XX   The invention relates to a fusion agent (Trojan antigen; TA) comprising a
CC   transport domain, two cleavage sites, a peptide epitope recognised by an
CC   antigen-specific receptor on an effector T-lymphocyte precursor cell and
CC   a biologically active agent, where there is a cleavage site between the
CC   peptide epitope and the biologically active agent and between each
CC   biologically active agent. The fusion agent is used to make a cell
CC   immunogenic or antigenic. It is also useful for preventing and treating
CC   an infectious disease such as viral, bacterial, protozoal, fungal or
CC   yeast disease, or proliferative disease such as cancer (e.g. melanoma,
CC   neural tissue, gastrointestinal, breast, lung, ovarian, testicular,
CC   prostate, cervical, bladder, vaginal, liver, renal, bone, haematological
CC   or vascular tissue cancer). The invention is used as vaccines. The
CC   present sequence is human carcinoembryonic antigen (CAE) specific HLA-A2-
CC   restricted minimal CTL epitope. This peptide is used in the
CC   exemplification of the invention
XX
XX   Sequence 9 AA;
SQ

Query Match      100.0%; Score 41; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. NO. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 IMIGVLGV 9
        |||||
Db      1 IMIGVLGV 9

RESULT 7
ABU04842
ID   ABU04842 standard; protein; 9 AA.
XX
AC   ABU04842;
XX
DT   29-JAN-2003 (first entry)
XX

Human expressed protein tag (EPT) #1508.
XX
DE
XX   Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW   protease; protease inhibitor; transporter; cytoskeletal protein;
KW   receptor; transcription factor; cancer; MHC;
KW   major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW   adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX
XX   Homo sapiens.
OS
XX
XX   WO200278524-A2.
PN
XX
XX   10-OCT-2002.
PD
XX
XX   28-MAR-2002; 2002WO-US009671.
PF
XX
XX   28-MAR-2001; 2001US-0279495P.
PR
XX   21-MAY-2001; 2001US-0292544P.
PR
XX   08-AUG-2001; 2001US-0310801P.
PR
XX   01-OCT-2001; 2001US-0326370P.
PR
XX   04-DEC-2001; 2001US-0336780P.
PR
XX   20-FEB-2002; 2002US-0358985P.
XX
XX   (ZYCO-) ZYCOS INC.
PA
XX
XX   Chicx RM, Tomlinson AJ, Urban RG;
PI
XX
XX   WPI; 2003-040607/03.
DR
XX
XX   New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
PT   cytoskeletal proteins, receptors or transcription factors), useful for
PT   treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
PT   leukemia.
XX
XX   Example 2; SEQ ID NO 1508; 134pp; English.
XX
XX   The invention describes a purified polypeptide, which comprises a
CC   fragment of a kinase, phosphatase, protease, protease inhibitor,
CC   transporter, cytoskeletal protein, receptor or transcription factor. The
CC   polypeptide is useful as an immunogenic composition for eliciting in a
CC   mammal an immunogenic response directed against any of the purified
CC   polypeptide. The purified polypeptide, or the antibody that binds to this
CC   polypeptide, is useful for treating cancer. The polypeptide is also
CC   useful for identifying compounds that binds to a naturally processed
CC   class I or class II MHC-binding polypeptide. The polypeptides and
CC   polynucleotides are particularly useful for treating or preventing
CC   myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
CC   lymphoma or leukaemia. These are also useful for screening agents for
CC   treating the above mentioned diseases. This sequence represents an
CC   expressed protein tag (EPT) isolated from human tissue for translational
CC   profiling. Note: This sequence does not appear in the printed
CC   specification but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
XX   Sequence 9 AA;
SQ

Query Match      100.0%; Score 41; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. NO. 1.4e+06;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 IMIGVLGV 9
        |||||
Db      1 IMIGVLGV 9

RESULT 8
ABU04846
ID   ABU04846 standard; protein; 9 AA.
XX
AC   ABU04846;
XX
DT   29-JAN-2003 (first entry)
XX
```

```
XX DE Human expressed protein tag (EPT) #1512.
XX DE
XX DE
KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX XX
XX PF 28-MAR-2002; 2002WO-US009671.
XX XX
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX XX
XX PA (ZYCO-) ZYCOS INC.
XX XX
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX XX
XX DR WPI; 2003-040607/03.
XX XX
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX XX
XX PS Example 2; SEQ ID NO 1512; 134pp; English.
XX XX
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 9 AA;
XX XX
XX Query Match 100.0%; Score 41; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX QY 1 IMIGVLGV 9
XX |||||
XX Db 1 IMIGVLGV 9
XX XX
XX RESULT 9
XX ABU03347
XX ID ASU03347 standard; protein; 9 AA.
XX AC ABU03347;
XX XX
XX DT 29-JAN-2003 (first entry)
```

```
XX DE Human expressed protein tag (EPT) #127.
XX DE
XX DE
KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
KW protease; protease inhibitor; transporter; cytoskeletal protein;
KW receptor; transcription factor; cancer; MHC;
KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX OS
XX OS Homo sapiens.
XX PN WO200278524-A2.
XX PD 10-OCT-2002.
XX XX
XX PF 28-MAR-2002; 2002WO-US009671.
XX XX
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX XX
XX PA (ZYCO-) ZYCOS INC.
XX XX
XX PI Chicx RM, Tomlinson AJ, Urban RG;
XX XX
XX DR WPI; 2003-040607/03.
XX XX
XX PT New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX PT cytoskeletal proteins, receptors or transcription factors), useful for
XX PT treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX PT leukemia.
XX XX
XX PS Claim 10; SEQ ID NO 127; 134pp; English.
XX XX
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX XX
XX SQ Sequence 9 AA;
XX XX
XX Query Match 100.0%; Score 41; DB 6; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX QY 1 IMIGVLGV 9
XX |||||
XX Db 1 IMIGVLGV 9
XX XX
XX RESULT 10
XX ABU04844
XX ID ABU04844 standard; protein; 9 AA.
XX AC ABU04844;
XX XX
XX DT 29-JAN-2003 (first entry)
```

```

XX DE Human expressed protein tag (EPT) #1510.
XX DE
XX KW Translational profiling; expressed protein tag; EPT; kinase; phosphatase;
XX KW protease; protease inhibitor; transporter; cytoskeletal protein;
XX KW receptor; transcription factor; cancer; MHC;
XX KW major histocompatibility complex; myeloma; colon cancer; gastric cancer;
XX KW adenocarcinoma; sarcoma; melanoma; lymphoma; leukaemia.
XX KW
XX OS Homo sapiens.
XX KW
XX KW WO200278524-A2.
XX KW
XX PD 10-OCT-2002.
XX KW
XX PF 28-MAR-2002; 2002WO-US009671.
XX KW
XX PR 28-MAR-2001; 2001US-0279495P.
XX PR 21-MAY-2001; 2001US-0292544P.
XX PR 08-AUG-2001; 2001US-0310801P.
XX PR 01-OCT-2001; 2001US-0326370P.
XX PR 04-DEC-2001; 2001US-0336780P.
XX PR 20-FEB-2002; 2002US-0358985P.
XX KW
XX PA (ZYCO-) ZYCOS INC.
XX KW
XX KW Chicx RM, Tomlinson AJ, Urban RG;
XX KW
XX DR WPI; 2003-040607/03.
XX KW
XX KW New polypeptides (e.g. kinases, phosphatases, proteases, transporters,
XX KW cytoskeletal proteins, receptors or transcription factors), useful for
XX KW treating cancer, e.g. colon cancer, gastric cancer, sarcoma, lymphoma or
XX KW leukemia.
XX KW
XX PS Example 2; SEQ ID NO 1510; 134pp; English.
XX KW
XX CC The invention describes a purified polypeptide, which comprises a
XX CC fragment of a kinase, phosphatase, protease, protease inhibitor,
XX CC transporter, cytoskeletal protein, receptor or transcription factor. The
XX CC polypeptide is useful as an immunogenic composition for eliciting in a
XX CC mammal an immunogenic response directed against any of the purified
XX CC polypeptide. The purified polypeptide, or the antibody that binds to this
XX CC polypeptide, is useful for treating cancer. The polypeptide is also
XX CC useful for identifying compounds that binds to a naturally processed
XX CC class I or class II MHC-binding polypeptide. The polypeptides and
XX CC polynucleotides are particularly useful for treating or preventing
XX CC myeloma, colon cancer, gastric cancer, adenocarcinoma, sarcoma, melanoma,
XX CC lymphoma or leukaemia. These are also useful for screening agents for
XX CC treating the above mentioned diseases. This sequence represents an
XX CC expressed protein tag (EPT) isolated from human tissue for translational
XX CC profiling. Note: This sequence does not appear in the printed
XX CC specification but was obtained in electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX KW
XX SQ Sequence 9 AA;
XX KW
XX KW Query Match 100.0%; Score 41; DB 6; Length 9;
XX KW Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX KW Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX KW
XX QY 1 IMIGVLGV 9
XX KW |||||
XX DB 1 IMIGVLGV 9
XX KW
XX KW RESULT 11
XX KW ABG74919
XX KW ID ABG74919 standard; peptide; 9 AA.
XX KW
XX AC ABG74919;
XX KW
XX KW 11-JUL-2003 (first entry)
XX KW
XX KW

```

```

XX KW melanoma-associated antigen MART-1 associated peptide.
XX DE
XX DE Dendritic cell; cell line; CD124; CD116; cytostatic; antirheumatic;
XX KW immunosuppressive; immunostimulatory; antibacterial; virucide;
XX KW antiparasitic; fungicide; dermatological; antiinflammatory; antianaemic;
XX KW nephrotropic; thyrotropic; antidiabetic; anthelmintic;
XX KW protozoacide allogenic; immunotherapeutic; humoral immune system;
XX KW cellular immune system; natural killer cell; CD4+ cell;
XX KW antigen cytotoxic T cell; proliferation; vaccine; infection; tumour;
XX KW autoimmune disease; Hashimoto's syndrome; insulin-dependent diabetes;
XX KW rheumatism; systemic lupus erythematosus; Goodpasture syndrome;
XX KW transplantation; melanoma-associated antigen; MART-1.
XX KW
XX OS Homo sapiens.
XX KW
XX KW WO2003023023-A1.
XX KW
XX PD 20-MAR-2003.
XX KW
XX PF 19-AUG-2002; 2002WO-EP009260.
XX KW
XX PR 17-AUG-2001; 2001DE-01039428.
XX KW
XX KW (NEMO-) NEMOD IMMUNOTHERAPIE AG.
XX KW
XX KW Goletz S, Scheper RJ, Masterson A, Pinedo HM;
XX KW WPI; 2003-301068/29.
XX KW
XX KW Preparation of dendritic cells, useful e.g. as antitumor or antimicrobial
XX KW vaccines, by treating CD124- and CD116-positive cells with stimulatory
XX KW molecules.
XX KW
XX PS Disclosure; Page 35; 89pp; German.
XX KW
XX CC This invention describes a novel method for preparing effective dendritic
XX CC cells or cell lines comprising treating cells of CD124- and CD116-
XX CC positive lines with at least one stimulatory molecule, applied at the
XX CC same time or sequentially. The products of the invention have cytostatic,
XX CC antirheumatic, immunosuppressive, immunostimulatory, antibacterial,
XX CC virucide, antiparasitic, fungicide, dermatological, antiinflammatory,
XX CC antianaemic, nephrotropic, thyrotropic, antidiabetic, anthelmintic and
XX CC protozoacide activity. The novel cell lines are useful: (a) as
XX CC (semi)allogenic immunotherapeutic agents; (b) for activating, inhibiting
XX CC or modulating the humoral and/or cellular immune systems; (c) for
XX CC stimulating natural killer, CD4+ and/or cytotoxic T cells; (d) for
XX CC processing and presenting antigens; and (e) to induce proliferation of
XX CC immune cells. Particularly they are used to treat or prevent, as
XX CC vaccines, infections (by viruses, bacteria, parasites, protozoa, prions
XX CC or helminths), tumours and/or autoimmune diseases (e.g. anaemia;
XX CC Hashimoto's syndrome; insulin-dependent diabetes; rheumatism; systemic
XX CC lupus erythematosus; Goodpasture syndrome and many others listed); also
XX CC in transplantation medicine and for diagnosis. Systems containing novel
XX CC cell lines are also useful for testing the immuno-activating, -inhibiting
XX CC and/or -modulating activities of substances and/or for analyzing the
XX CC biology of dendritic cells. This sequence represents a peptide associated
XX CC with the melanoma-associated antigen MART-1 which is described in the
XX CC disclosure of the invention
XX KW
XX SQ Sequence 9 AA;
XX KW
XX KW Query Match 100.0%; Score 41; DB 6; Length 9;
XX KW Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX KW Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX KW
XX QY 1 IMIGVLGV 9
XX KW |||||
XX DB 1 IMIGVLGV 9
XX KW
XX KW RESULT 12
XX KW ADD84718

```

ID ADD84718 standard; peptide; 9 AA.  
AC ADD84718;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human carcinoembryonic antigen (CEA) epitope peptide SEQ ID NO:7.  
XX  
XX identification;  
KW class I major histocompatibility complex-binding fragment;  
KW class I MHC molecule; class I MHC-binding fragment; cytostatic; cancer;  
KW human, carcinoembryonic antigen; CEA; epitope.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
XX WO2003082317-A1.  
PN  
XX  
PD 09-OCT-2003.  
XX  
PF 20-MAR-2003; 2003WO-US0008427.  
XX  
PR 22-MAR-2002; 2002US-0366822P.  
XX  
PA (ZYCO-) ZYCOS INC.  
PA (AVET ) AVENTIS PASTEUR INC.  
XX  
XX Chicz RM, Tomlinson AJ;  
XX  
XX WPI; 2003-902907/82.  
DR  
XX  
XX Identifying a class I major histocompatibility complex (MHC)-binding  
PT fragment of a polypeptide comprises isolating an MHC molecule, eluting  
PT the peptide from the molecule, and identifying the peptide as a  
PT polypeptide fragment.  
XX  
XX Claim 10; SEQ ID NO 7; 98pp; English.  
XX  
XX The present invention describes a method for identifying a class I major  
CC histocompatibility complex (MHC)-binding fragment of a polypeptide by  
CC isolating from the tissue/cell line a class I MHC molecule bound to a  
CC peptide, where the peptide is a class I MHC-binding fragment of the  
CC polypeptide, eluting the peptide from the class I MHC molecule, and  
CC identifying the peptide as a fragment of the polypeptide. A class I MHC-  
CC binding fragment has cytostatic activity. Compositions and methods from  
CC the present invention can be used in diagnosing, preventing or treating  
CC cancer. The method may also be used in identifying peptides involved in  
CC the pathogenesis of or protection from diseases associated with  
CC expression of class I MHC molecules. The present sequence represents a  
CC human carcinoembryonic antigen (CEA) epitope peptide, which is used in  
CC the exemplification of the present invention.  
XX  
SQ Sequence 9 AA;  
  
Query Match 100.0%; Score 41; DB 7; Length 9;  
Best Local Similarity 100.0%; Pred. NO. 1.4e+06;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 IMIGVLVGV 9  
DB 1 IMIGVLVGV 9  
|||||  
  
RESULT 13  
AAW70047  
ID AAW70047 standard; peptide; 10 AA.  
AC  
XX  
XX AAW70047;  
XX  
DT 22-OCT-1998 (first entry)  
XX  
DE CEA derived HLA-A2.1 binding peptide 4 (residues 690-699).  
XX

KW Cytotoxic T lymphocyte; CTL; major histocompatibility complex; MHC;  
KW human leukocyte antigen; HLA; tumour associated antigen; cancer;  
KW antigen presenting cell; APC; immunogenic peptide; immune disorder;  
KW viral infection; AIDS; hepatitis; bacterial infection; malaria; CEA;  
KW fungal infection; tuberculosis; melanoma; carcinoembryonic antigen.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
XX WO9833888-A1.  
PN  
XX  
PD 06-AUG-1998.  
XX  
PF 30-JAN-1998; 98WO-US001959.  
XX  
PR 31-JAN-1997; 97US-0036696P.  
XX  
PA (EPIM-) EPIMUNE INC.  
XX  
XX Tsai V, Southwood S, Sidney J, Sette A, Celis E;  
XX WPI; 1998-437445/37.  
DR  
XX  
XX Production of antigen-specific cytotoxic T cells - by incubating  
PT immunogenic peptide(s) from antigen that binds class I major  
PT histocompatibility complex molecules with pre-treated antigen presenting  
PT cells.  
XX  
XX Example 6; Page 75; 104pp; English.  
XX  
XX Sequences shown in AAW70044 to AAW70052 represent peptides derived from  
CC carcinoembryonic antigen (CEA). The peptides can bind to a human  
CC leukocyte antigen (HLA), HLA-A2.1 and are used to exemplify the method of  
CC invention of producing antigen-specific cytotoxic T cells (CTLs) in  
CC vitro. The method comprises contacting immunogenic peptides from an  
CC antigen that binds class I major histocompatibility complex (MHC)  
CC molecules with antigen presenting cells (APCs) pretreated with  
CC pretreatment growth factors, and incubating the APCs with purified CD8  
CC cells in the presence of at least 2 incubation growth factors, thereby  
CC producing antigen-specific CTLs. A method for specifically killing target  
CC cells in a human patient is also provided which comprises obtaining a  
CC fluid sample containing CTLs from a patient, contacting the cytotoxic T  
CC cells with APCs pretreated with pre-treatment growth factors, where the  
CC APCs comprise class I MHC molecules. The pretreated APCs are incubated  
CC with the cytotoxic growth factors, thereby producing activated CTLs which  
CC are contacted with a carrier to form a composition. The composition can  
CC then be administered to the patient. The activated CTLs can be used for  
CC treating cancers, immune disorders, viral infections, AIDS, hepatitis,  
CC bacterial infection, fungal infection, malaria or tuberculosis  
XX  
SQ Sequence 10 AA;  
  
Query Match 100.0%; Score 41; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. NO. 0.13;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 IMIGVLVGV 9  
DB 2 IMIGVLVGV 10  
|||||  
  
RESULT 14  
AAW70051  
ID AAW70051 standard; peptide; 10 AA.  
XX  
AC AAW70051;  
XX  
DT 22-OCT-1998 (first entry)  
XX  
DE CEA derived HLA-A2.1 binding peptide 8 (residues 691-700).  
XX  
KW Cytotoxic T lymphocyte; CTL; major histocompatibility complex; MHC;  
KW human leukocyte antigen; HLA; tumour associated antigen; cancer;  
XX

KW antigen presenting cell; APC; immunogenic peptide; immune disorder;  
KW viral infection; AIDS; hepatitis; bacterial infection; malaria; CEA;  
KW fungal infection; tuberculosis; melanoma; carcinoembryonic antigen.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
XX WO9833888-A1.  
XX  
XX 06-AUG-1998.  
XX  
XX 30-JAN-1998; 98WO-US001959.  
XX  
XX 31-JAN-1997; 97US-0036696P.  
XX  
XX (EPIM-) EPIMUNE INC.  
XX  
XX Tsai V, Southwood S, Sidney J, Sette A, Celis E;  
XX WPI; 1998-437445/37.  
XX  
XX Production of antigen-specific cytotoxic T cells - by incubating  
PT immunogenic peptide(s) from antigen that binds class I major  
PT histocompatibility complex molecules with pre-treated antigen presenting  
PT cells.  
XX  
XX Example 6; Page 75; 104pp; English.  
XX  
XX Sequences shown in AAW70044 to AAW70052 represent peptides derived from  
CC carcinoembryonic antigen (CEA). The peptides can bind to a human  
CC leukocyte antigen (HLA), HLA-A2.1 and are used to exemplify the method of  
CC invention of producing antigen-specific cytotoxic T cells (CTLs) in  
CC vitro. The method comprises contacting immunogenic peptides from an  
CC antigen that binds class I major histocompatibility complex (MHC)  
CC molecules with antigen presenting cells (APCs) pretreated with  
CC pretreatment growth factors, and incubating the APCs with purified CD8  
CC cells in the presence of at least 2 incubation growth factors, thereby  
CC producing antigen-specific CTLs. A method for specifically killing target  
CC cells in a human patient is also provided which comprises obtaining a  
CC fluid sample containing CTLs from a patient, contacting the cytotoxic T  
CC cells with APCs pretreated with pre-treatment growth factors, where the  
CC APCs comprise class I MHC molecules. The pretreated APCs are incubated  
CC with the cytotoxic growth factors, thereby producing activated CTLs which  
CC are contacted with a carrier to form a composition. The composition can  
CC then be administered to the patient. The activated CTLs can be used for  
CC treating cancers, immune disorders, viral infections, AIDS, hepatitis,  
CC bacterial infection, fungal infection, malaria or tuberculosis  
XX  
SQ Sequence 10 AA;  
Query Match 100.0%; Score 41; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 0.13;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 IMIGVLGV 9  
| | | | |  
Db 1 IMIGVLGV 9  
RESULT 15  
AA47672  
ID AAY47672 standard; peptide; 10 AA.  
XX  
XX AAY47672;  
AC  
XX 01-DEC-1999 (first entry)  
DT  
XX Immunogenic peptide having a human leukocyte antigen binding motif #2283.  
XX Human leukocyte antigen; binding; immunogenic; glycoprotein; MHC; HLA;  
KW immune response; T cell activation; major histocompatibility complex;  
KW cytotoxic T lymphocyte; CTL; tumour rejection; viral infection; cancer;  
KW prostate cancer; hepatitis B; hepatitis C; AIDS; renal carcinoma;

KW vaccine; immunisation.  
XX  
XX Synthetic.  
OS Homo sapiens.  
XX  
XX WO9945954-A1.  
XX  
XX 16-SEP-1999.  
XX  
XX 13-MAR-1998; 98WO-US005039.  
XX  
XX 13-MAR-1998; 98WO-US005039.  
XX  
XX (EPIM-) EPIMUNE INC.  
XX  
XX Sette A, Kubo RT, Sidney J, Celis E, Grey HM, Southwood S;  
XX WPI; 1999-551214/46.  
XX  
XX New immunogenic peptides with HLA binding motif, useful in treatment and  
PT diagnosis of cancers and viral diseases.  
XX  
XX Claim 1; Page 119; 150pp; English.  
XX  
XX AAY45390 to AAY48214 represent specifically claimed immunogenic peptides  
CC having a human major histocompatibility complex (MHC) Class I (also known  
CC as human leukocyte antigen (HLA)) binding motif. The immunogenic peptides  
CC can bind to a specific HLA allele (i.e. HLA-A subtypes HLA-A2.1, A1, A3.2  
CC or A24.1 or HLA-B or C) and induce a cytotoxic T cell response against  
CC the antigen from which the peptide is derived. Cytotoxic T lymphocytes  
CC (CTLs) which destroy antigen-bearing cells are normally induced by an  
CC antigen in the form of a peptide fragment bound to a HLA molecule, rather  
CC than the intact foreign antigen itself, and are particularly important in  
CC tumour rejection and in fighting viral infections. The peptides are  
CC therefore useful therapeutically to treat or prevent viral infections and  
CC cancers in mammals (especially humans) e.g. prostate cancer, hepatitis B  
CC and C, AIDS, and renal carcinoma. They can be administered as vaccines to  
CC elicit an immune response in individuals susceptible or otherwise at risk  
CC of viral infection or cancer, or used to treat chronic or acute  
CC conditions. They are also useful diagnostically, and can be used to  
CC induce a cytotoxic T cell response, by contacting a cytotoxic T cell with  
CC the peptide e.g. to produce CTLs ex vivo for infusion back into a  
CC patient. The polynucleotides encoding the immunogenic peptides are also  
CC useful therapeutically and for immunisation as above  
XX  
SQ Sequence 10 AA;  
Query Match 100.0%; Score 41; DB 2; Length 10;  
Best Local Similarity 100.0%; Pred. No. 0.13;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 IMIGVLGV 9  
| | | | |  
Db 1 IMIGVLGV 9  
Search completed: August 6, 2004, 08:34:13  
Job time : 54 secs



A;Accession: A21777  
A;Molecule type: mRNA  
A;Residues: 1-702 <BEA>  
A;Cross-references: GB:M29540; NID:G180222; PIDN:AAA51967.1; PID:G180223  
R;Barnett, T.; Goebel, S.J.; Nothdurft, M.A.; Elting, J.J.  
Genomics 3, 59-66, 1988  
A;Title: Carcinoembryonic antigen family: characterization of cDNAs coding for NCA and (

A;Accession: A21777  
A;Molecule type: mRNA  
A;Residues: 1-702 <BEA>  
A;Cross-references: GB:M29540; NID:G180222; PIDN:AAA51967.1; PID:G180223  
A;Note: the authors translated the codon GTG for residue 130 as Leu  
E;Oikawa, S.; Nakazato, H.; Kosaki, G.  
Biochem. Biophys. Res. Commun. 142, 511-518, 1987  
A;Title: Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA se  
A;Reference number: A25845; MUID:87128144; PMID:3814146  
A;Accession: A25845  
A;Molecule type: mRNA  
A;Residues: 5-702 <OIK>  
A;Cross-references: GB:M15042; NID:G180198; PIDN:AAA51963.1; PID:G180199  
E;Oikawa, S.  
submitted to the EMBL Data Library, September 1989  
A;Reference number: S08106  
A;Accession: S08106  
A;Molecule type: mRNA  
A;Residues: 5-319, 321-702 <O12>  
A;Cross-references: EMBL:X16455; NID:G29854; PIDN:CAA34474.1; PID:g825638  
E;Barnett, T.  
submitted to the EMBL Data Library, September 1991  
A;Description: Genomic DNA sequence upstream of the translational start of the carcinoe  
A;Reference number: S31737



A;Accession: S28058  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-357 <PLA>  
A;Cross-references: EMBL:Z18278  
C;Superfamily: octopamine receptor type I  
C;Keywords: G protein-coupled receptor; glycoprotein; neurotransmitter receptor; transmembrane protein

Query Match 87.8%; Score 36; DB 2; Length 357;  
Best Local Similarity 55.6%; Pred. No. 30;  
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9  
:|:|:|  
Db 285 LMVGILIGV 293

RESULT 5  
I37107  
5-HT5A serotonin receptor - human  
C;Species: Homo sapiens (man)  
C;Date: 29-May-1998 #sequence\_revision 29-May-1998 #text\_change 21-Jul-2000  
C;Accession: I37107  
R;Rees, S.; den Daas, I.; Foord, S.; Goodson, S.; Bull, D.; Kilpatrick, G.; Lee, M.  
FEBS Lett. 355, 242-246, 1994  
A;Title: Cloning and characterisation of the human 5-HT5A serotonin receptor.  
A;Reference number: I37107; MUID:95080386; PMID:7988681  
A;Accession: I37107  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-357 <RES>  
A;Cross-references: EMBL:X81411; NID:G541776; PIDN:CAA57168.1; PID:G784990  
C;Genetics:  
A;Gene: 5-HT5A  
A;Introns: 247/3  
C;Superfamily: octopamine receptor type I

Query Match 87.8%; Score 36; DB 2; Length 357;  
Best Local Similarity 55.6%; Pred. No. 30;  
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9  
:|:|:|  
Db 285 LMVGILIGV 293

RESULT 6  
B47472  
5-hydroxytryptamine 5 alpha receptor - rat  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 21-Jan-1994 #sequence\_revision 18-Nov-1994 #text\_change 05-Nov-1999  
C;Accession: B47472  
R;Erlander, M.G.; Lovenberg, T.W.; Baron, B.M.; de Lecea, L.; Danielson, P.E.; Racke, M.  
Proc. Natl. Acad. Sci. U.S.A. 90, 3452-3456, 1993  
A;Title: Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in the rat brain.  
A;Reference number: A47472; MUID:93234515; PMID:7682702  
A;Accession: B47472  
A;Status: preliminary  
A;Molecule type: nucleic acid  
A;Residues: 1-357 <ERL>  
A;Cross-references: GB:L10072; NID:G310072; PIDN:AAA40615.1; PID:G310073  
A;Experimental source: hypothalamus  
A;Note: sequence extracted from NCBI backbone (NCBIN:129674, NCBIP:129677)  
C;Superfamily: octopamine receptor type I  
C;Keywords: G protein-coupled receptor; transmembrane protein

Query Match 87.8%; Score 36; DB 2; Length 357;  
Best Local Similarity 55.6%; Pred. No. 30;  
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9  
:|:|:|  
Db 285 LMVGILIGV 293

RESULT 7  
T48486  
hypothetical protein T28J14.90 - Arabidopsis thaliana  
C;Species: Arabidopsis thaliana (mouse-ear cress)  
C;Date: 20-Apr-2000 #sequence\_revision 20-Apr-2000 #text\_change 20-Apr-2000  
C;Accession: T48486  
R;Bevan, M.; Murphy, G.; Ridley, P.; Hudson, S.; Bancroft, I.; Mewes, H.W.; Rudd, S.; Le  
submitted to the Protein Sequence Database, April 2000  
A;Reference number: Z24493  
A;Accession: T48486  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-553 <BEV>  
A;Cross-references: EMBL:AL163652  
A;Experimental source: cultivar Columbia; BAC clone T28J14  
C;Genetics:  
A;Map position: 5  
A;Introns: 37/1; 80/2; 104/2; 280/1; 344/3; 387/1  
A;Note: T28J14.90

Query Match 87.8%; Score 36; DB 2; Length 553;  
Best Local Similarity 77.8%; Pred. No. 46;  
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9  
:|:|:|  
Db 232 IIVGVILGV 240

RESULT 8  
AH2911  
hypothetical protein Atu2729 [imported] - Agrobacterium tumefaciens (strain C58, Dupont)  
C;Species: Agrobacterium tumefaciens  
C;Date: 11-Jan-2002 #sequence\_revision 11-Jan-2002 #text\_change 18-Nov-2002  
C;Accession: AH2911  
R;Wood, D.W.; Setubal, J.C.; Kaul, R.; Monks, D.; Chen, L.; Wood, G.E.; Chen, Y.; Woo, Y.;  
erage, G.; Gillet, W.; Grant, C.; Guenther, D.; Kuttyavin, T.; Levy, R.; Li, M.; McClellan,  
; Karp, P.; Romero, P.; Zhang, S.  
Science 294, 2317-2323, 2001  
A;Authors: Yoo, H.; Tao, Y.; Biddle, P.; Jung, M.; Krespan, W.; Perry, M.; Gordon-Kamm,  
ster, E.W.  
A;Title: The Genome of the Natural Genetic Engineer Agrobacterium tumefaciens C58.  
A;Reference number: AB2577; MUID:21608550; PMID:11743193  
A;Accession: AH2911  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-95 <KUR>  
A;Cross-references: GB:AE008688; PIDN:AAL43710.1; PID:G17741239; GSPDB:GN00186  
A;Experimental source: strain C58 (Dupont)  
C;Genetics:  
A;Gene: Atu2729  
A;Map position: circular chromosome

Query Match 85.4%; Score 35; DB 2; Length 95;  
Best Local Similarity 66.7%; Pred. No. 13;  
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9  
:|:|:|  
Db 52 IMLGVLLGI 60

RESULT 9  
C69174  
conserved hypothetical protein MTH561 - Methanobacterium thermoautotrophicum (strain Del  
C;Species: Methanobacterium thermoautotrophicum  
C;Date: 05-Dec-1997 #sequence\_revision 05-Dec-1997 #text\_change 24-Sep-1999  
C;Accession: C69174  
R;Smith, D.R.; Doucette-Stamm, L.A.; Deloughery, C.; Lee, H.; Dubois, J.; Aldredge, T.;  
; Qiu, D.; Spadafora, R.; Vicaire, R.; Wang, Y.; Wierzbowski, J.; Gibson, R.; Jiwani, N.  
ki, S.; Church, G.M.; Daniels, C.J.; Mao, J.; Rice, P.; Noelling, J.; Reeve, J.N.

J. Bacteriol. 179, 7135-7155, 1997  
A;Title: Complete genome sequence of *Methanobacterium thermoautotrophicum* Delta H: functional  
A;Reference number: A69000; MUID:98037514; PMID:9371463  
A;Accession: C69174  
A;Status: preliminary; nucleic acid sequence not shown; translation not shown  
A;Molecule type: DNA  
A;Residues: 1-192 <MTH>  
A;Cross-references: GB:AE000839; GB:AE000666; NID:G2621637; PIDN:AAB85067.1; PID:G262163  
A;Experimental source: strain Delta H  
C;Genetics:  
A;Gene: MTH561  
C;Superfamily: conserved hypothetical protein MJ0645

Query Match 85.4%; Score 35; DB 2; Length 192;  
Best Local Similarity 66.7%; Pred. No. 25;  
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
:|:|:|:|  
Db 175 VWIGVLIGV 183

RESULT 10  
S38744  
serotonin receptor 5B - rat  
N;Alternate names: 5-hydroxytryptamine receptor 5B (5-HT<sub>5B</sub>)  
C;Species: *Rattus norvegicus* (Norway rat)  
C;Date: 19-May-1994 #sequence\_revision 10-Nov-1995 #text\_change 05-Nov-1999  
C;Accession: S38744; A47472  
R;Wisden, W.; Parker, E.M.; Mahle, C.D.; Grisel, D.A.; Nowak, H.P.; Yocca, F.D.; Felder, R.;  
FEBS Lett. 333, 25-31, 1993  
A;Title: Cloning and characterization of the rat 5-HT<sub>5B</sub> receptor. Evidence that the 5-HT<sub>5B</sub>  
A;Reference number: S38744; MUID:94039744; PMID:8224165  
A;Accession: S38744  
A;Molecule type: mRNA  
A;Residues: 1-369 <MIS>  
R;Rindler, M.G.; Lovenberg, T.W.; Baron, B.M.; de Lecea, L.; Danielson, P.E.; Racke, M.;  
Proc. Natl. Acad. Sci. U.S.A. 90, 3452-3456, 1993  
A;Title: Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially  
A;Reference number: A47472; MUID:93234515; PMID:7682702  
A;Accession: A47472  
A;Status: preliminary  
A;Molecule type: nucleic acid  
A;Residues: 1-176, 177-369 <ERL>  
A;Cross-references: GB:L10073; NID:G310074; PIDN:AAA40616.1; PID:G310075  
A;Experimental source: hypothalamus  
A;Note: sequence extracted from NCBI backbone (NCBIN:129665, NCBIP:129668)  
C;Superfamily: octopamine receptor type I  
C;Keywords: G protein-coupled receptor; transmembrane protein

Query Match 85.4%; Score 35; DB 2; Length 369;  
Best Local Similarity 55.6%; Pred. No. 47;  
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
:|:|:|:|  
Db 297 MWVGILIGV 305

RESULT 11  
I48231  
serotonin receptor 5B - mouse  
N;Alternate names: 5-hydroxytryptamine 5B receptor (5HT<sub>5B</sub>-5C)  
C;Species: *Mus musculus* (house mouse)  
C;Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 05-Nov-1999  
C;Accession: I48231  
R;Matthews, H.; Boschert, U.; Amlaiky, N.; Grailhe, R.; Plassat, J.L.; Muscatelli, F.; Ma  
Mol. Pharmacol. 43, 313-319, 1993  
A;Title: Mouse 5-hydroxytryptamine<sub>5A</sub> and 5-hydroxytryptamine<sub>5B</sub> receptors define a new fa  
A;Reference number: I48231; MUID:93196607; PMID:8450829  
A;Accession: I48231  
A;Status: preliminary; translated from GB/EMBL/DDBU  
A;Molecule type: mRNA

A;Residues: 1-370 <RES>  
A;Cross-references: EMBL:X69867; NID:G288735; PIDN:CAA49501.1; PID:G288736  
C;Superfamily: octopamine receptor type I  
C;Keywords: G protein-coupled receptor; glycoprotein; neurotransmitter receptor; transmem  
Query Match 85.4%; Score 35; DB 2; Length 370;  
Best Local Similarity 55.6%; Pred. No. 47;  
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
:|:|:|:|  
Db 298 MWVGILIGV 306

RESULT 12  
B83420  
probable two-component sensor PA1798 [imported] - *Pseudomonas aeruginosa* (strain PA01)  
C;Species: *Pseudomonas aeruginosa*  
C;Date: 15-Sep-2000 #sequence\_revision 15-Sep-2000 #text\_change 31-Dec-2000  
C;Accession: B83420  
R;Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warrenner, P.; Hickey, M.J.; Br  
adman, S.; Yuan, Y.; Brody, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Harbig, K.; Lim,  
.; Lory, S.; Olson, M.V.  
Nature 406, 959-964, 2000  
A;Title: Complete genome sequence of *Pseudomonas aeruginosa* PA01, an opportunistic patho  
A;Reference number: A82950; MUID:20437337; PMID:10984043  
A;Accession: B83420  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-428 <STO>  
A;Cross-references: GB:AE004506; GB:AE004091; NID:G9947780; PIDN:AAG05187.1; GSPDB:GN001  
A;Experimental source: strain PA01  
C;Genetics:  
A;Gene: PA1798

Query Match 85.4%; Score 35; DB 2; Length 428;  
Best Local Similarity 66.7%; Pred. No. 55;  
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
:|:|:|:|  
Db 140 ILLGVLVGI 148

RESULT 13  
AD2390  
hypothetical protein asr4576 [imported] - *Nostoc* sp. (strain PCC 7120)  
C;Species: *Nostoc* sp. PCC 7120  
A;Note: *Nostoc* sp. strain PCC 7120 is a synonym of *Anabaena* sp. strain PCC 7120  
C;Date: 14-Dec-2001 #sequence\_revision 14-Dec-2001 #text\_change 09-Dec-2002  
C;Accession: AD2390  
R;Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi  
Nakazaki, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S.  
DNA Res. 8, 205-213, 2001  
A;Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing *Cyanobacterium* An  
A;Reference number: AB1807; MUID:21595285; PMID:11759840  
A;Accession: AD2390  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-58 <KUR>  
A;Cross-references: GB:BA000019; PIDN:BA876375.1; PID:G17133813; GSPDB:GN00179  
A;Experimental source: strain PCC 7120  
C;Genetics:  
A;Gene: asr4576

Query Match 82.9%; Score 34; DB 2; Length 58;  
Best Local Similarity 66.7%; Pred. No. 12;  
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
:|:|:|:|  
Db 20 IVVGVLIGV 28

```
RESULT 14
A97309
probable membrane protein [imported] - Clostridium acetobutylicum
C;Species: Clostridium acetobutylicum
C;Date: 14-Sep-2001 #sequence_revision 14-Sep-2001 #text_change 14-Sep-2001
C;Accession: A97309
R;Nolling, J.; Breton, G.; Omelchenko, M.V.; Markarova, K.S.; Zeng, Q.; Gibson, R.; Lee,
J.; Daly, M.J.; Bennett, G.N.; Koonin, E.V.; Smith, D.R.
J. Bacteriol. 183, 4823-4838, 2001
A;Title: Genome Sequence and Comparative Analysis of the Solvent-Producing Bacterium Clo
A;Reference number: A96900; MUID:21359325; PMID:21359325
A;Accession: A97309
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-203 <KUR>
A;Cross-references: GB:AE001437; PIDN:AAK81260.1; PID:G15026409; GSPDB:GN00168
A;Experimental source: Clostridium acetobutylicum ATCC824
C;Genetics:
A;Gene: CAC3328

Query Match 82.9%; Score 34; DB 2; Length 203;
Best Local Similarity 77.8%; Pred. No. 41;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 IMIGVLVGV 9
Db 12 IMIGCIVGV 20

RESULT 15
A44233
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 1 - fall armyworm mitochondrion (fra
N;Alternate names: NADH-ubiquinone oxidoreductase chain 1
C;Species: mitochondrion Spodoptera frugiperda (fall armyworm)
C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 03-Jun-2002
C;Accession: A44233
R;Fashley, D.P.; Ke, L.D.
Mol. Biol. Evol. 9, 1061-1075, 1992
A;Title: Sequence evolution in mitochondrial ribosomal and ND-1 genes in lepidoptera: im
A;Reference number: A44233; MUID:93061985; PMID:1435234
A;Accession: A44233
A;Molecule type: DNA
A;Residues: 1-235 <PAS>
A;Cross-references: GB:M76713; NID:G343352; PIDN:AAA32079.1; PID:G552886
A;Note: sequence extracted from NCBI backbone (NCBIP:118938)
C;Genetics:
A;Gene: ND-1
A;Genome: mitochondrion
A;Start codon: ATA
C;Superfamily: NADH dehydrogenase (ubiquinone) chain 1
C;Keywords: membrane-associated complex; mitochondrion; NAD; oxidative phosphorylation;

Query Match 82.9%; Score 34; DB 2; Length 235;
Best Local Similarity 66.7%; Pred. No. 47;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1 IMIGVLVGV 9
Db 14 LIIGILVGV 22

Search completed: August 6, 2004, 08:35:27
Job time : 18 secs
```

This page blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 6, 2004, 08:32:42 ; Search time 13 Seconds  
(without alignments)  
36.049 Million cell updates/sec

Title: US-09-458-302B-193  
Perfect score: 41  
Sequence: 1 IMIGVLGV 9

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_42.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	41	100.0	702	CEA5_HUMAN	P06731 homo sapien
2	36	87.8	357	SH5A_HUMAN	P47898 homo sapien
3	36	87.8	357	SH5A_MOUSE	P30966 mus musculus
4	36	87.8	357	SH5A_RAT	P35364 rattus norv
5	35	85.4	370	SH5B_MOUSE	P31387 mus musculus
6	35	85.4	370	SH5B_RAT	P35365 rattus norv
7	34	82.9	238	RNFE_AZOVI	Q9f5y1 azotobacter
8	34	82.9	265	CEA7_HUMAN	Q14002 homo sapien
9	34	82.9	429	URAA_ECOLI	P33780 escherichia
10	34	82.9	633	NAH2_YEAST	Q04121 saccharomyc
11	34	82.9	685	ST41_ARATH	Q9fv46 arabidopsis
12	33	80.5	78	YK61_LACPL	Q88x18 lactobacill
13	33	80.5	333	PTHB_ERWAM	O32522 erwinia amy
14	33	80.5	660	Y390_MYCGE	Q49430 mycoplasma
15	33	80.5	677	ST42_ARATH	O8gyh8 arabidopsis
16	32	78.0	73	Y010_BACCR	O812v8 bacillus ce
17	32	78.0	73	Y1E2_BACAA	O81v17 bacillus an
18	32	78.0	174	NU6M_HYLLA	Q95710 hyllobates l
19	32	78.0	205	Y001_BHPH1	P51700 bacterioph
20	32	78.0	241	RNFE_PEST	Q9evn2 pseudomonas
21	32	78.0	241	Y513_METJA	O59733 methanococc
22	32	78.0	245	COBS_PGEAE	O91463 pseudomonas
23	32	78.0	252	CEA3_HUMAN	P40198 homo sapien
24	32	78.0	278	UPK_SULSO	Q97x94 sulfobobus
25	32	78.0	291	UPK2_STRCO	Q9k407 streptomyce
26	32	78.0	317	NU1M_DICDI	Q37313 dictyosteli
27	32	78.0	319	PTHB_ECOLI	P56580 escherichia
28	32	78.0	414	CP51_IGSOR	Q02315 issatchenki
29	32	78.0	421	HEMA_CVBLF	P33468 bovine coro
30	32	78.0	424	HEMA_CVBLG	P59711 bovine coro
31	32	78.0	424	HEMA_CVBG9	Q66165 bovine coro
32	32	78.0	424	HEMA_CVBL9	P59710 bovine coro
33	32	78.0	424	HEMA_CVBLS	Q9qar6 bovine coro

## RESULT 1

CEA5\_HUMAN STANDARD; PRT; 702 AA.

AC P06731;

DT 01-JAN-1988 (Rel. 06, Created)

DT 01-DEC-1992 (Rel. 24, Last sequence update)

DT 15-MAR-2004 (Rel. 43, Last annotation update)

DE Carcinoembryonic antigen-related cell adhesion molecule 5 precursor

DE (Carcinoembryonic antigen) (CEA) (Meconium antigen 100) (CD66e

DE antigen).

GN CEACAM5 OR CEA.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI\_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=90258861; PubMed=2342461;

RA Schrewe H., Thompson J., Bona M., Hefta L.J.F., Maruya A.,

RA Hasseuer M., Shively J.E., von Kleist S., Zimmermann W.;

RT "Cloning of the complete gene for carcinoembryonic antigen: analysis

RT of its promoter indicates a region conveying cell type-specific

RT expression.";

RL Mol. Cell. Biol. 10:2738-2748(1990).

RL [2]

RP SEQUENCE FROM N.A.

RX MEDLINE=88038876; PubMed=3670312;

RA Beauchemin N., Benchimol S., Cournoyer D., Fuks A., Stanners C.P.;

RT "Isolation and characterization of full-length functional cDNA clones

RT for human carcinoembryonic antigen.";

RL Mol. Cell. Biol. 7:3221-3230(1987).

RL [3]

RP SEQUENCE FROM N.A.

RX MEDLINE=89122014; PubMed=3220478;

RA Barnett T., Goebel S.J., Nothdurft M.A., Elting J.J.;

RT "Carcinoembryonic antigen family: characterization of cDNAs coding

RT for NCA and CEA and suggestion of nonrandom sequence variation in

RL their conserved loop-domains.";

RL Genomics 3:59-66(1988).

RL [4]

RP SEQUENCE OF 5-702 FROM N.A.

RX MEDLINE=87128144; PubMed=3814146;

RA Oikawa S., Nakazato H., Kosaki G.;

RT "Primary structure of human carcinoembryonic antigen (CEA) deduced

RT from cDNA sequence.";

RL Biochem. Biophys. Res. Commun. 142:511-518(1987).

RL [5]

RP SEQUENCE OF 331-702 FROM N.A.

RX MEDLINE=87204247; PubMed=3033671;

RA Zimmermann W., Ortlieb B., Friedrich R., von Kleist S.;

RT "Isolation and characterization of cDNA clones encoding the human

RT carcinoembryonic antigen reveal a highly conserved repeating

RT structure.";

RL Proc. Natl. Acad. Sci. U.S.A. 84:2960-2964(1987).

CC -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.

CC -!- TISSUE SPECIFICITY: Found in adenocarcinomas of endodermally

## ALIGNMENTS

34	32	78.0	424	1	HEMA_CVBLU	Q8v437 bovine coro
35	32	78.0	424	1	HEMA_CVBLY	P31613 bovine coro
36	32	78.0	424	1	HEMA_CVBM	P15776 bovine coro
37	32	78.0	424	1	HEMA_CVBQ	P59709 bovine coro
38	32	78.0	424	1	HEMA_CVHOC	P30215 human coron
39	32	78.0	424	1	HEMA_CVP67	Q8b826 porcine hem
40	32	78.0	424	1	HEMA_CVPIA	Q8j8p9 porcine hem
41	32	78.0	428	1	HEMA_CVMA5	P31615 murine coro
42	32	78.0	430	1	HEMA_CVMS	P31614 murine coro
43	32	78.0	431	1	HEMA_CVMDV	O92367 murine coro
44	32	78.0	438	1	PBUX_BACSU	P42086 bacillus su
45	32	78.0	439	1	HEMA_CVPV	O91262 puffinosis

derived digestive system epithelium and fetal colon.  
-!- PPM: COMPLEX IMMUNOREACTIVE GLYCOPROTEIN WITH A MW OF 180 kDa  
CC COMPRISING 60% CARBOHYDRATE.  
CC -!- SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.  
CC -!- SIMILARITY: Contains 7 immunoglobulin-like domains.  
CC -!- DATABASE: NAME=PRO; NOTE=CD guide CD66e entry;  
CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cd66e.htm".  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC ENBL; M17303; AAB59513.1; -;  
DR ENBL; M59262; AAA62835.1; ALT SEQ.  
DR ENBL; M59255; AAA62835.1; JOINED.  
DR ENBL; M59256; AAA62835.1; JOINED.  
DR ENBL; M59257; AAA62835.1; JOINED.  
DR ENBL; M59258; AAA62835.1; JOINED.  
DR ENBL; M59259; AAA62835.1; JOINED.  
DR ENBL; M59260; AAA62835.1; JOINED.  
DR ENBL; M59261; AAA62835.1; JOINED.  
DR ENBL; M59709; -; NOT\_ANNOTATED\_CDS.  
DR ENBL; M59710; -; NOT\_ANNOTATED\_CDS.  
DR ENBL; M29540; AAA51967.1; -;  
DR ENBL; M16455; CAA34474.1; -;  
DR ENBL; M15042; AAA51963.1; -;  
DR ENBL; M16234; AAA51972.1; -;  
DR PIR; A36319; A36319.  
DR PDB; 1E07; 04-JUL-00.  
DR Genew; HGNC:1817; CEACAMS.  
DR MIM; 114890; -;  
DR GO; GO:0005887; C:integral to plasma membrane; TAS.  
DR InterPro; IPR007110; Ig-like.  
DR Pfam; PF00047; ig; 6.  
DR PROSITE; PS50835; IG\_LIKE; 6.  
KW Immunoglobulin domain; Glycoprotein; Lipoprotein; GPI-anchor;  
KW Membrane; Signal; Repeat; 3D-structure.  
FT SIGNAL 1 34  
FT CHAIN 35 685  
FT PROPEP 686 702  
FT DOMAIN 35 144  
FT DOMAIN 146 238  
FT DOMAIN 324 415  
FT DOMAIN 416 498  
FT DOMAIN 502 593  
FT DOMAIN 594 677  
FT LIPID 685 685  
FT CARBOHYD 104 104  
FT CARBOHYD 115 115  
FT CARBOHYD 152 152  
FT CARBOHYD 182 182  
FT CARBOHYD 197 197  
FT CARBOHYD 204 204  
FT CARBOHYD 208 208  
FT CARBOHYD 246 246  
FT CARBOHYD 256 256  
FT CARBOHYD 274 274  
FT CARBOHYD 288 288  
FT CARBOHYD 292 292  
FT CARBOHYD 309 309  
FT CARBOHYD 330 330  
FT CARBOHYD 351 351  
FT CARBOHYD 360 360  
FT CARBOHYD 375 375  
FT CARBOHYD 432 432  
FT CARBOHYD 466 466  
FT CARBOHYD 480 480

FT CARBOHYD 508 508 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 529 529 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 553 553 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 560 560 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 580 580 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 612 612 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 650 650 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 665 665 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CONFLICT 320 320 MISSING (IN REF. 4).  
SQ SEQUENCE 702 AA; 76795 MW; 6299AE26CDDDB5C CRC64;  
Query Match 100.0%; Score 41; DB 1; Length 702;  
Best Local Similarity 100.0%; Pred. No. 4.1;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 IMIGVLGV 9  
DB 691 IMIGVLGV 699  
|||||  
RESULT 2  
SH5A HUMAN STANDARD; PRT; 357 AA.  
ID SH5A HUMAN AC P47898;  
DT 01-FEB-1996 (Rel. 33, Created)  
DT 01-FEB-1996 (Rel. 33, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE 5-hydroxytryptamine 5A receptor (5-HT-5A) (Serotonin receptor)  
DE (5-HT-5).  
GN HTR5A.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=95080386; PubMed=7988681;  
RA Rees S., den Daas I., Poord S., Goodson S., Bull D., Kilpatrick G.,  
RA Lee M.;  
RT "Cloning and characterisation of the human 5-HT5A serotonin  
receptor.";  
RL FEBS Lett. 355:242-246(1994).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Brain;  
RA Publ H.L. III, Ikeda S.R., Aronstam R.S.;  
RT "cDNA clones of human proteins involved in signal transduction  
sequenced by the Guthrie cDNA resource center ([www.cdna.org](http://www.cdna.org)).";  
RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.  
CC -!- FUNCTION: This is one of the several different receptors for 5-  
hydroxytryptamine (serotonin), a biogenic hormone that functions  
as a neurotransmitter, a hormone, and a mitogen. The activity of  
this receptor is mediated by G proteins.  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
CC STRONGEST TO THE OTHER 5HT-5 SUBTYPE RECEPTORS.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC ENBL; X81411; CAA57168.1; -;  
DR ENBL; X81412; CAA57168.1; JOINED.  
DR ENBL; AF498985; AAM21132.1; -;  
DR PIR; I37107; I37107  
DR Genew; HGNC:5300; HTR5A.  
DR MIM; 601305; -;  
DR GO; GO:0005887; C:integral to plasma membrane; TAS.  
DR GO; GO:0004993; F:serotonin receptor activity; TAS.



GO: GO:0007186; P:G-protein coupled receptor protein signalin. . .; TAS.  
 DR InterPro; IPR000276; GPCR\_Rhodpsn.  
 DR Pfam; PF00001; 7tm 1; 1.  
 DR PRINTS; PR00237; GPCRHHODPSN.  
 DR PROSITE; PS00237; G-PROTEIN RECP\_F1\_1; 1.  
 DR PROSITE; PS0262; G-PROTEIN RECP\_F1\_2; 1.  
 KW G-protein coupled receptor; Transmembrane; Glycoprotein;  
 Multigene family.  
 FT DOMAIN 1 40 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 41 63 1 (POTENTIAL).  
 FT DOMAIN 64 78 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 79 99 2 (POTENTIAL).  
 FT DOMAIN 100 115 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 116 137 3 (POTENTIAL).  
 FT DOMAIN 138 158 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 159 181 4 (POTENTIAL).  
 FT DOMAIN 182 198 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 199 219 5 (POTENTIAL).  
 FT DOMAIN 220 282 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 283 303 6 (POTENTIAL).  
 FT DOMAIN 304 320 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 321 341 7 (POTENTIAL).  
 FT DOMAIN 342 357 CYTOPLASMIC (POTENTIAL).  
 FT CARBOHYD 6 6 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 21 21 BY SIMILARITY.  
 FT DISULFID 120 192  
 SQ SEQUENCE 357 AA; 40255 MW; 92F0A78C69169790 CRC64;  
 Query Match 87.8%; Score 36; DB 1; Length 357;  
 Best Local Similarity 55.6%; Pred. No. 19;  
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 IMIGVLGV 9  
 :|:|:|:  
 Db 285 LMVGILGV 293  
 RESULT 3  
 SH5A MOUSE STANDARD; PRT; 357 AA.  
 ID SH5A\_MOUSE  
 AC P30966;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-JUL-1993 (Rel. 26, Last sequence update)  
 DT 15-JUL-1998 (Rel. 36, Last annotation update)  
 DE 5-hydroxytryptamine 5A receptor (5-HT-5A) (Serotonin receptor)  
 DE (5-HT-5).  
 GN HTR5A OR 5HT5A.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=93099851; PubMed=1464308;  
 RA Plassat J.-L., Boschart U., Amlaiky N., Hen R.;  
 RT "The mouse 5HT5 receptor reveals a remarkable heterogeneity within  
 the 5HT1D receptor family";  
 RL EMBO J. 11:4779-4786(1992).  
 RN [2]  
 RP CHARACTERIZATION.  
 RC TISSUE=Brain;  
 RX MEDLINE=93196607; PubMed=8450829;  
 RA Matthes H., Boschart U., Amlaiky N., Grailhe R., Plassat J.-L.,  
 RA Muscatelli F., Mattei M.-G., Hen R.;  
 RT "Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors  
 define a new family of serotonin receptors: cloning, functional  
 expression, and chromosomal localization";  
 RL Mol. Pharmacol. 43:313-319(1993).  
 CC -!- FUNCTION: This is one of the several different receptors for 5-  
 hydroxytryptamine (serotonin), a biogenic hormone that functions  
 as a neurotransmitter, a hormone, and a mitogen. The activity of  
 this receptor is mediated by G proteins.

CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -!- TISSUE SPECIFICITY: Expressed predominantly in the central nervous  
 system; in the cerebral cortex, hippocampus, habenula, olfactory  
 bulb and granular layer of the cerebellum.  
 CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
 CC STRONGEST TO THE OTHER 5HT-5 SUBTYPE RECEPTORS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 CC EMBL; Z18278; CAA79155.1; -  
 DR MGD; MG1:96283; Htr5a.  
 DR InterPro; IPR000276; GPCR\_Rhodpsn.  
 DR Pfam; PF00001; 7tm 1; 1.  
 DR PRINTS; PR00237; GPCRHHODPSN.  
 DR PROSITE; PS00237; G-PROTEIN RECP\_F1\_1; 1.  
 DR PROSITE; PS0262; G-PROTEIN RECP\_F1\_2; 1.  
 KW G-protein coupled receptor; Transmembrane; Glycoprotein;  
 Multigene family.  
 FT DOMAIN 1 40 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 41 63 1 (POTENTIAL).  
 FT DOMAIN 64 78 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 79 99 2 (POTENTIAL).  
 FT DOMAIN 100 115 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 116 137 3 (POTENTIAL).  
 FT DOMAIN 138 158 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 159 181 4 (POTENTIAL).  
 FT DOMAIN 182 198 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 199 219 5 (POTENTIAL).  
 FT DOMAIN 220 282 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 283 303 6 (POTENTIAL).  
 FT DOMAIN 304 320 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 321 341 7 (POTENTIAL).  
 FT DOMAIN 342 357 CYTOPLASMIC (POTENTIAL).  
 FT CARBOHYD 6 6 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 21 21 BY SIMILARITY.  
 FT DISULFID 120 192  
 SQ SEQUENCE 357 AA; 40804 MW; 5F5D856AC477BFAC CRC64;  
 Query Match 87.8%; Score 36; DB 1; Length 357;  
 Best Local Similarity 55.6%; Pred. No. 19;  
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 IMIGVLGV 9  
 :|:|:|:  
 Db 285 LMVGILGV 293  
 RESULT 4  
 SH5A RAT STANDARD; PRT; 357 AA.  
 ID SH5A\_RAT  
 AC P35364;  
 DT 01-JUN-1994 (Rel. 29, Created)  
 DT 01-JUN-1994 (Rel. 29, Last sequence update)  
 DT 01-NOV-1995 (Rel. 32, Last annotation update)  
 DE 5-hydroxytryptamine 5A receptor (5-HT-5A) (Serotonin receptor)  
 DE (REC17).  
 GN HTR5A OR 5HT5A.  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Sprague-Dawley; TISSUE=Brain;  
 RX MEDLINE=93234515; PubMed=7682702;  
 RA Erlander M.G., Lovenberg T.W., Baron B.M., de Lecea L.,  
 RA Danielson P.E., Racke M., Slone A.L., Siegel B.W., Foye P.E.,

RA Cannon K., Burns J.E., Sutcliffe G.J.:  
 RT "Two members of a distinct subfamily of 5-hydroxytryptamine receptors  
 RL differentially expressed in rat brain."  
 RL Proc. Natl. Acad. Sci. U.S.A. 90:3452-3456(1993).  
 CC -!- FUNCTION: This is one of the several different receptors for 5-  
 CC hydroxytryptamine (serotonin), a biogenic hormone that functions  
 CC as a neurotransmitter, a hormone, and a mitogen. The activity of  
 CC this receptor is mediated by G proteins.  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -!- TISSUE SPECIFICITY: Central nervous system.  
 CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
 CC STRONGEST TO THE OTHER SHT-5 SUBTYPE RECEPTORS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL; L10072; AAA40615.1; -.  
 CC PIR; B47472; B47472.  
 CC InterPro; IPR000276; GPCR\_Rhodpsn.  
 CC Pfam; PF00001; 7tm.1.1.  
 CC PRINTS; PR00237; GPCRHOPOPSN.  
 CC PROSITE; PS00237; G-PROTEIN\_RECEP\_F1\_1; 1.  
 CC PROSITE; PS0262; G-PROTEIN\_RECEP\_F1\_2; 1.  
 CC G-protein coupled receptor; Transmembrane; Glycoprotein;  
 CC Multigene family.  
 CC DOMAIN 1 40 EXTRACELLULAR (POTENTIAL).  
 CC TRANSSEM 41 63  
 CC DOMAIN 64 78  
 CC TRANSSEM 79 99  
 CC DOMAIN 100 115  
 CC TRANSSEM 116 137  
 CC DOMAIN 138 158  
 CC TRANSSEM 159 181  
 CC DOMAIN 182 198  
 CC TRANSSEM 199 219  
 CC DOMAIN 220 282  
 CC TRANSSEM 283 303  
 CC DOMAIN 304 320  
 CC TRANSSEM 321 341  
 CC DOMAIN 342 357  
 CC TRANSSEM 357 370  
 CC CARBOHYD 6  
 CC DISULFID 21  
 CC BY SIMILARITY.  
 CC SEQUENCE 357 AA; 40672 MW; 8C498A50C88408B5 CRC64;

Query Match 87.8%; Score 36; DB 1; Length 357;  
 Best Local Similarity 55.6%; Pred. No. 19; Mismatches 0; Indels 0; Gaps 0;  
 Matches 5; Conservative 4;

QY 1 IMIGVLVGV 9  
 :|:|:|:|

Db 285 LMVGILIGV 293

RESULT 5

SH5B MOUSE  
 ID \_SH5B\_MOUSE STANDARD; PRT; 370 AA.  
 AC P31387;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-JUL-1993 (Rel. 26, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE 5-hydroxytryptamine 5B receptor (5-HT-5B) (Serotonin receptor).  
 GN HTR5B OR 5HT5B.  
 OS Mus musculus (Mouse).  
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 CC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 CC NCBI\_taxid=10090;  
 RN [1]

RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RA MEDLINE=93196607; PubMed=8450829;  
 RA Matthes H., Boscher U., Amlaiky N., Grailhe R., Plassat J.-L.,  
 RA Muscatelli F., Mattei M.-G., Hen R.;  
 RT "Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors  
 RT define a new family of serotonin receptors: cloning, functional  
 RT expression, and chromosomal localization."  
 RL Mol. Pharmacol. 43:313-319(1993).  
 CC -!- FUNCTION: This is one of the several different receptors for  
 CC 5-hydroxytryptamine (serotonin), a biogenic hormone that functions  
 CC as a neurotransmitter, a hormone, and a mitogen. The activity of  
 CC this receptor is mediated by G proteins. Probably involved in  
 CC anxiety and depression.  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -!- TISSUE SPECIFICITY: Expressed predominantly in the central nervous  
 CC system; in the hippocampus, habenula, and the dorsal raphe.  
 CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
 CC STRONGEST TO THE OTHER SHT-5 SUBTYPE RECEPTORS.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL; X69867; CAA49501.1; -.  
 CC PIR; I48231; I48231.  
 CC MGD; MGI:96284; Htr5b.  
 CC InterPro; IPR000276; GPCR\_Rhodpsn.  
 CC Pfam; PF00001; 7tm.1.1.  
 CC PRINTS; PR00237; GPCRHOPOPSN.  
 CC PROSITE; PS00237; G-PROTEIN\_RECEP\_F1\_1; 1.  
 CC PROSITE; PS0262; G-PROTEIN\_RECEP\_F1\_2; 1.  
 CC G-protein coupled receptor; Transmembrane; Glycoprotein;  
 CC Multigene family.  
 CC DOMAIN 1 52 EXTRACELLULAR (POTENTIAL).  
 CC TRANSSEM 53 75  
 CC DOMAIN 76 90  
 CC TRANSSEM 91 111  
 CC DOMAIN 112 128  
 CC TRANSSEM 129 150  
 CC DOMAIN 151 171  
 CC TRANSSEM 172 194  
 CC DOMAIN 195 211  
 CC TRANSSEM 212 232  
 CC DOMAIN 233 296  
 CC TRANSSEM 296 316  
 CC DOMAIN 317 333  
 CC TRANSSEM 334 354  
 CC DOMAIN 355 370  
 CC TRANSSEM 370 405  
 CC CARBOHYD 5  
 CC DISULFID 127  
 CC BY SIMILARITY.  
 CC SEQUENCE 370 AA; 41201 MW; 0553C62B12DAAD84 CRC64;

Query Match 85.4%; Score 35; DB 1; Length 370;  
 Best Local Similarity 55.6%; Pred. No. 29;  
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9  
 :|:|:|:|

Db 298 MMVGILIGV 306

RESULT 6

SH5B\_RAT  
 ID \_SH5B\_RAT STANDARD; PRT; 370 AA.  
 AC P35365;  
 DT 01-JUN-1994 (Rel. 29, Created)  
 DT 01-JUN-1994 (Rel. 29, Last sequence update)  
 DT 01-OCT-1996 (Rel. 34, Last annotation update)

DE 5-hydroxytryptamine 5B receptor (5-HT-5B) (Serotonin receptor) (MR22).  
GN HTR5B OR 5HT5B.  
OS Rattus norvegicus [Rat].  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Sprague-Dawley; TISSUE=Brain;  
RX MEDLINE=93234515; PubMed=7682702;  
RA Erlander M.G., Lovenberg T.W., Baron B.M., de Lecea L., Foye P.E.,  
RA Danielson P.E., Racke W., Stone A.L., Siegel B.W., Foye P.E.,  
RA Cannon K., Burns J.E., Sutcliffe G.J.;  
RT "Two members of a distinct subfamily of 5-hydroxytryptamine receptors  
RT differentially expressed in rat brain";  
RL Proc. Natl. Acad. Sci. U.S.A. 90:3452-3456(1993).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=94039744; PubMed=8224165;  
RA Wisden W., Parker E.M., Mahle C.D., Grisel D.A., Nowak H.P.,  
RA Yocca F.D., Feiler C.C., Seeburg P.H., Voigt M.M.;  
RT "Cloning and characterization of the rat 5-HT5B receptor. Evidence  
RT that the 5-HT5B receptor couples to a G protein in mammalian cell  
RT membranes";  
RL FEBS Lett. 333:25-31(1993).  
CC -!- FUNCTION: This is one of the several different receptors for 5-  
CC hydroxytryptamine (serotonin), a biogenic hormone that functions  
CC as a neurotransmitter, a hormone, and a mitogen. The activity of  
CC this receptor is mediated by G proteins. Probably involved in  
CC anxiety and depression.  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -!- TISSUE SPECIFICITY: Brain; in the CA1 region of hippocampus, the  
CC medial habenula, and raphe nuclei.  
CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
CC STRONGEST TO THE OTHER 5HT-5 SUBTYPE RECEPTORS.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; L10073; AAA40616.1; -;  
CC PIR; S38744; S38744.  
CC InterPro; IPR000276; GPCR\_Rhodpsn.  
CC Pfam; PF00001; 7tm\_1; 1.  
CC PRINTS; PR00237; GPCR\_RHODOPSIN.  
CC PROSITE; PS00237; G PROTEIN RECEPTOR FL1; 1.  
CC PROSITE; PS00262; G PROTEIN RECEPTOR FL2; 1.  
CC G-protein coupled receptor; Transmembrane; Glycoprotein;  
KW Multigene family.  
FT DOMAIN 1 52 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 53 75 1 (POTENTIAL).  
FT DOMAIN 76 90 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 91 111 2 (POTENTIAL).  
FT DOMAIN 112 128 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 129 150 3 (POTENTIAL).  
FT DOMAIN 151 171 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 172 194 4 (POTENTIAL).  
FT DOMAIN 195 211 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 212 232 5 (POTENTIAL).  
FT DOMAIN 233 295 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 296 316 6 (POTENTIAL).  
FT DOMAIN 317 333 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 334 354 7 (POTENTIAL).  
FT DOMAIN 355 370 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 371 412 N-LINKED (GLCNAC...) (POTENTIAL).  
FT CARBOHYD 127 205 BY SIMILARITY.  
FT DISULFID 127 205  
SQ SEQUENCE 370 AA; 41122 MW; 8EC5F789BFD647E5 CRC64;  
Query Match 85.4%; Score 35; DB 1; Length 370;

Best Local Similarity 55.6%; Pred. No. 29;  
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 1 IMIGVLVGV 9  
DB 298 MMVGILIGV 306  
RESULT 7  
RNPE AZOVI STANDARD; PRT; 238 AA.  
AC Q9FSY1;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Electron transport complex protein rnfE (Nitrogen fixation protein  
DE rnfE).  
GN RNFE.  
OS Azotobacter vinelandii.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;  
OC Pseudomonadaceae; Azotobacter.  
OX NCBI\_TaxID=354;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=DJ;  
RA Rubio L.M., Rangaraj P., Roberts G.P., Ludden P.W.;  
RT "Cloning and mutational analysis of the Azotobacter vinelandii gene  
RT encoding the dinitrogenase gamma subunit";  
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
CC -!- FUNCTION: Required for nitrogen fixation. May be part of a  
CC membrane complex functioning as an intermediate in the electron  
CC transport to nitrogenase (By similarity).  
CC -!- SUBUNIT: Composed of at least six subunits; rnfA, rnfB, rnfC,  
CC rnfD, rnfE and rnfG (By similarity).  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein. Inner membrane  
CC (Potential).  
CC -!- SIMILARITY: Belongs to the nqrDE/rnfAE family.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; AF302049; AAG29820.1; -;  
CC HAMAP; MF\_00478; -; 1.  
CC InterPro; IPR003667; Rnf Nqr.  
CC Pfam; PF02508; Rnf-Nqr; 1.  
CC KW Nitrogen fixation; Electron transport; Transmembrane; Inner membrane.  
FT TRANSMEM 41 63 POTENTIAL.  
FT TRANSMEM 84 104 POTENTIAL.  
FT TRANSMEM 106 126 POTENTIAL.  
FT TRANSMEM 141 161 POTENTIAL.  
FT TRANSMEM 195 215 POTENTIAL.  
SQ SEQUENCE 238 AA; 25527 MW; 5701ADD4D1D55734 CRC64;  
Query Match 82.9%; Score 34; DB 1; Length 238;  
Best Local Similarity 66.7%; Pred. No. 31;  
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
QY 1 IMIGVLVGV 9  
DB 84 VMIGVIAGV 92  
RESULT 8  
CEA7 HUMAN STANDARD; PRT; 265 AA.  
ID CEA7\_HUMAN Q15148; O15149; Q9UPJ2;  
AC Q14002; O15148; O15149; Q9UPJ2;  
DT 15-JUL-1999 (Rel. 38, Created)  
DT 15-JUL-1999 (Rel. 38, Last sequence update)

DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Carcinoembryonic antigen-related cell adhesion molecule 7 precursor  
DE (Carcinoembryonic antigen CGM2).  
GN CEACAM7 OR CGM2.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]\_TaxID=9606;  
RN SEQUENCE FROM N.A. (ISOFORM 2A).  
RX MEDLINE=95105177; PubMed=7806520;  
RA Thompson J., Zimmermann W., Nollau P., Neumaier M., Weber-Arden J.,  
RA Schrewe H., Craig I., Willcocks T.;  
RT "CGM2, a member of the carcinoembryonic antigen gene family is down-  
regulated in colorectal carcinomas.";  
RL J. Biol. Chem. 269:32924-32931(1994).  
RN [2]  
RN SEQUENCE FROM N.A. (ISOFORM 2A).  
RC TISSUE=Colon mucosa;  
RX MEDLINE=97280695; PubMed=9135022;  
RA Thompson J., Seitz M., Chastre E., Ditter M., Aldrian C., Gespach C.,  
RA Zimmermann W.;  
RT "Down-regulation of carcinoembryonic antigen family member 2  
expression is an early event in colorectal tumorigenesis.";  
RL Cancer Res. 57:1776-1784(1997).  
RN [3]  
RN SEQUENCE FROM N.A. (ISOFORMS 2A AND 2B).  
RA Zhou G.Q.;  
RT "Two isoforms of CEA gene family member 2 (CGM2) mRNA are co-expressed  
in small and large intestine mucosa epithelium and in colorectal tumor  
cells.";  
RL Submitted (JUN-1997) to the EMBL/GenBank/DBJ databases.  
RN [4]  
RN SEQUENCE FROM N.A. (ISOFORMS 2A AND 2B).  
RA Lamerdin J.E., McCready P.M., Skowronski E., Viswanathan V.,  
RA Burkhardt-Schultz K., Gordon L., Dias J., Ramirez M., Stillwagen S.,  
RA Phan H., Velasco N., Do L., Regala W., Terry A., Garnes J.,  
RA Dangnanan L., Erler A., Christensen M., Georgescu A., Avila J., Liu S.,  
RA Attix C., Andreise T., Frankheim M., Amico-Keller G., Coefield J.,  
RA Duarte S., Lucas S., Bruce R., Thomas P., Quan G., Krommiller B.,  
RA Arellano A., Saunders C., Ow D., Nolan M., Trong S., Kobayashi A.,  
RA Olsen A.S., Carrano A.V.;  
RT "Sequence analysis of a 2.5 Mb region in 19q13.2 containing a  
clustered CEA/PSG gene family.";  
RL Submitted (OCT-1998) to the EMBL/GenBank/DBJ databases.  
CC -|- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor  
(Potential).  
CC -|- ALTERNATIVE PRODUCTS:  
CC Event=Alternative splicing; Named isoforms=2;  
CC Name=2a;  
CC IsoId=Q14002-1; Sequence=displayed;  
CC Name=2b;  
CC IsoId=Q14002-2; Sequence=VSP\_002488;  
CC -|- TISSUE SPECIFICITY: Strongly down-regulated in colonic  
adenocarcinomas.  
CC -|- SIMILARITY: Belongs to the immunoglobulin superfamily. CEA family.  
CC -|- SIMILARITY: Contains 1 immunoglobulin-like V-type domain.  
CC -|- SIMILARITY: Contains 1 immunoglobulin-like C2-type domain.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; L31792; AAA66186.1; -;  
CC EMBL; X98311; CAA66955.1; -;  
CC EMBL; AF006622; AAB62924.1; -;  
CC EMBL; AF006623; AAB62925.1; -;  
CC EMBL; AC005797; AAC62825.1; -;  
CC EMBL; AC005797; AAC62826.1; -;

DR PIR; A55811; A55811.  
DR Genew; HGNC:1819; CEACAM7.  
DR GO; GO:0016021; C:integral to membrane; TAS.  
DR GO; GO:0005886; C:plasma membrane; TAS.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003599; IG.  
DR SMART; SM00409; IG; 2.  
DR PROSITE; PS50835; IG LIKE; 1.  
KW Immunoglobulin domain; Antigen; Membrane; Signal; Glycoprotein;  
KW Lipoprotein; GPI-anchor; Repeat; Alternating splicing.  
FT SIGNAL 1 34  
FT CHAIN 35 242  
FT PROPEP 243 265  
FT DOMAIN 35 142  
FT DOMAIN 146 233  
FT DISULFID 168 216  
FT LIPID 242 242  
FT CARBOHYD 57 57  
FT CARBOHYD 85 85  
FT CARBOHYD 105 105  
FT CARBOHYD 112 112  
FT CARBOHYD 174 174  
FT CARBOHYD 183 183  
FT CARBOHYD 198 198  
FT VARSPLIC 143 235  
FT CONFLICT 40 40  
FT CONFLICT 71 71  
FT CONFLICT 120 120  
FT CONFLICT 235 235  
SQ SEQUENCE 265 AA; 29379 MW; B6B836F66BD10D3B CRC64;  
Query Match 82.9%; Score 34; DB 1; Length 265;  
Best Local Similarity 77.8%; Pred. No. 34;  
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1 IMIGVLGV 9  
DB 254 IMIGVLGM 262  
RESULT 9  
URAA\_ECOLI STANDARD; PRT; 429 AA.  
ID URAA\_ECOLI STANDARD; PRT; 429 AA.  
AC P33780.  
DT 01-FEB-1994 (Rel. 28, Created)  
DT 01-FEB-1994 (Rel. 28, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Uracil permease (Uracil transporter).  
GN URAA OR B2497 OR Z3760 OR ECS3359.  
OS Escherichia coli, and  
OS Escherichia coli O157:H7.  
OC Escherichia coli O157:H7.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
OC Enterobacteriaceae; Escherichia.  
OX NCBI\_TaxID=562, 83334;  
RN [1]\_TaxID=562, 83334;  
RN SEQUENCE FROM N.A.  
RC STRAIN=K12;  
RX MEDLINE=95238271; PubMed=7721693;  
RA Andersen P.S., Frees D., Fast R., Mygind B.;  
RT "Uracil uptake in Escherichia coli K-12: isolation of uraA mutants  
and cloning of the gene.";  
RL J. Bacteriol. 177:2008-2013(1995).  
RN [2]  
RN SEQUENCE FROM N.A.  
RC STRAIN=K12;  
RX MEDLINE=97426617; PubMed=9278503;  
RA Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,  
RA Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,  
RA Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,  
RA Mau B., Shao Y.;  
RT "The complete genome sequence of Escherichia coli K-12.";

Science 277:1453-1474(1997).  
[3]  
SEQUENCE FROM N.A.  
RC STRAIN=K12;  
RX MEDLINE=97349980; PubMed=9205837;  
RA Yamamoto Y., Aiba H., Baba T., Hayashi K., Inada T., Isono K.,  
RA Itoh T., Kimura S., Kitagawa M., Makino K., Miki T., Mitsuhashi N.,  
RA Mizobuchi K., Mori H., Nakade S., Nakamura Y., Nashimoto H.,  
RA Oshima T., Oyama S., Saito N., Sampei G., Satoh Y., Sivasundaram S.,  
RA Tagami H., Takahashi H., Takeda J., Takemoto K., Uehara K., Wada C.,  
RA Yamagata S., Horiuchi T.;  
RT "Construction of a contiguous 874-kb sequence of the Escherichia coli  
RT - K12 genome corresponding to 50.0-68.8 min on the linkage map and  
RT analysis of its sequence features.";  
RL DNA Res. 4:91-113(1997).  
[4]  
SEQUENCE FROM N.A.  
RX STRAIN=O157:H7 / EDL933 / ATCC 700927;  
RC MEDLINE=21074935; PubMed=11206551;  
RA Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D.,  
RA Rose D.J., Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A.,  
RA Posfai G., Hackett J., Klink S., Boutin A., Shao Y., Miller L.,  
RA Grobeck E.J., Davis N.W., Lim A., Dimalanta E.T., Potamoudis K.,  
RA Apodaca J., Anantharaman T.S., Lin J., Yen G., Schwartz D.C.,  
RA Welch R.A., Blattner F.R.;  
RT "Genome sequence of enterohaemorrhagic Escherichia coli O157:H7";  
RL Nature 409:529-533(2001).  
[5]  
SEQUENCE FROM N.A.  
RC STRAIN=O157:H7 / RMD 0509952;  
RX MEDLINE=21156231; PubMed=11258796;  
RA Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,  
RA Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T.,  
RA Lida T., Takami H., Honda T., Sasakawa C., Ogasawara N., Yasunaga T.,  
RA Kuhara S., Shiba T., Hattori M., Shinagawa H.;  
RT "Complete genome sequence of enterohemorrhagic Escherichia coli  
RT O157:H7 and genomic comparison with a laboratory strain K-12.";  
RL DNA Res. 8:11-22(2001).  
CC -!- FUNCTION: Transport of uracil in the cell.  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein. Inner membrane.  
CC -!- SIMILARITY: BELONGS TO THE XANTHINE/URACIL PERMEASES FAMILY.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; X73586; CAAS1992.1; -;  
CC EMBL; AE000336; AAC75550.1; -;  
CC EMBL; D90878; BAA16385.1; -;  
CC EMBL; AG005479; AAG57607.1; -;  
CC EMBL; AF002561; BAB36782.1; -;  
CC PIR; A56265; A56265.  
CC PIR; C85893; C85893.  
CC PIR; G91048; G91048.  
CC EcoGene; EGI2129; uraA.  
CC InterPro; IPR006042; Xan\_ur\_permease.  
CC InterPro; IPR006043; XanUrac/vitC.  
CC Pfam; PF00860; xan\_ur\_permease; 1.  
CC TIGRFAMs; TIGR00801; ncs2; 1.  
CC PROSITE; PS01116; XANTH URACIL PERMEASE; 1.  
KW Transmembrane; Transport; Inner membrane; Complete proteome.  
FT TRANSMEM 29 49 POTENTIAL.  
FT TRANSMEM 65 85 POTENTIAL.  
FT TRANSMEM 88 108 POTENTIAL.  
FT TRANSMEM 127 147 POTENTIAL.  
FT TRANSMEM 159 179 POTENTIAL.  
FT TRANSMEM 182 202 POTENTIAL.  
FT TRANSMEM 228 248 POTENTIAL.  
FT TRANSMEM 300 320 POTENTIAL.

FT TRANSMEM 325 345 POTENTIAL.  
FT TRANSMEM 366 386 POTENTIAL.  
FT TRANSMEM 392 412 POTENTIAL.  
SQ SEQUENCE 429 AA; 45060 MW; 18045190C960C674 CRC64;  
Query Match 82.9%; Score 34; DB 1; Length 429;  
Best Local Similarity 87.5%; Pred. No. 50;  
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 IMIGVLVG 8  
Db 185 ILIGVLVG 192  
RESULT 10  
NAH2 YEAST  
ID NAH2 YEAST STANDARD; PRT; 633 AA.  
AC Q04121;  
DT 30-MAY-2000 (Rel. 39, Last sequence update)  
DT 30-MAY-2000 (Rel. 39, Last annotation update)  
DE Mitochondrial sodium/hydrogen exchanger (Mitochondrial Na(+)/H(+) exchanger).  
DE ExchangeR).  
DE NHA2 OR NHA1 OR YDR456W OR D9461.40.  
OS Saccharomyces cerevisiae (Baker's yeast).  
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;  
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.  
OX NCBI\_TaxID=4932;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Dietrich F.S., Mulligan J., Allen E., Araujo R., Aviles E., Berno A.,  
RA Carpenter J., Chen E., Cherry J.M., Chung E., Duncan M.,  
RA Hunnicke-Smith S., Hyman R., Komp C., Lashkari D., Lew H., Lin D.,  
RA Mosedale D., Nakahara K., Namath A., Oefner P., Oh C., Petel F.X.,  
RA Roberts D., Schramm S., Schroeder M., Shogren T., Shroff N.,  
RA Winant A., Yelton M., Botstein D., Davis R.W.;  
RL Submitted (AUG-1995) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98175963; PubMed=9507001;  
RA Numata M., Petrecca K., Lake N., Orłowski J.;  
RT "Identification of a mitochondrial Na+/H+ exchanger.";  
RL J. Biol. Chem. 273:6951-6959(1998).  
CC -!- FUNCTION: Electroneutral exchange of protons for Na(+) and K(+) across the mitochondrial inner membrane. Contributes to organellar volume and calcium homeostasis.  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein. Mitochondrial.  
CC -!- SIMILARITY: Belongs to the Na(+)/H(+) exchanger family.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; U33007; AAB64861.1; -;  
CC PIR; S69734; S69734.  
CC GerOnline; 140948; -;  
CC SGD; S0002864; NHX1.  
CC GO; GO:0005770; C:late endosome; IDA.  
CC GO; GO:0015077; P:monovalent inorganic cation transporter act. .; IDA.  
CC GO; GO:0016197; P:endosome transport; IMP.  
CC GO; GO:0030004; P:monovalent inorganic cation homeostasis; IMP.  
CC GO; GO:0015672; P:monovalent inorganic cation transport; IMP.  
CC GO; GO:0007035; P:vacuolar acidification; IMP.  
CC InterPro; IPR006153; Na\_H\_porter.  
CC InterPro; IPR004709; NaH\_exchang.  
CC Pfam; PF00999; Na\_H\_exchanger; 1.  
CC PRINTS; PR01084; NAHEXCHNGR.  
CC TIGRFAMs; TIGR00840; b\_cpai; 1.  
KW Transmembrane; Transport; Antiport; Sodium transport; Mitochondrion.



```

FT TRANSMEM 406 426 POTENTIAL.
FT TRANSMEM 434 454 POTENTIAL.
FT TRANSMEM 473 493 POTENTIAL.
FT DOMAIN 518 642 STAS.
FT CONFLICT 229 229 L -> Q (IN REF. 4).
FT CONFLICT 344 344 A -> P (IN REF. 1).
FT CONFLICT 368 368 E -> D (IN REF. 1).
SQ SEQUENCE 685 AA; 75095 MW; 8C0087229BC39ADD CRC64;

Query Match 82.9%; Score 34; DB 1; Length 685;
Best Local Similarity 88.9%; Pred. No. 74;
Matches 8; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 IMIGVLGV 9
Db 477 IEIGVLGV 485

RESULT 12
YK61_LACPL STANDARD; PRT; 78 AA.
AC Q88Vf8;
DT 15-MAR-2004 (Rel. 43, Created)
DT 15-MAR-2004 (Rel. 43, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Hypothetical UPF0154 protein lp_2061.
GN LP_2061.
OS Lactobacillus plantarum.
OC Bacteria; Firmicutes; Lactobacillales; Lactobacillaceae;
OC Lactobacillus.
OX NCBI_TaxID=1590;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=NCIMB 8826 / WCFS1;
RX MEDLINE=22480296; PubMed=12566566;
RA Kleerebezem M., Boekhorst J., van Kranenburg R., Molenaar D.,
RA Kuipers O.P., Leer R., Tarchini R., Peters S.A., Sandbrink H.M.,
RA Fiers M.W.E.J., Stiekema W., Klein Lankhorst R.M., Bron P.A.,
RA Hoffer S.M., Nierop Groot M.N., Kerkhoven R., De Vries M., Ursing B.,
RA De Vos W.M., Siezen R.J.;
RT "Complete genome sequence of Lactobacillus plantarum WCFS1.";
RL Proc. Natl. Acad. Sci. U.S.A. 100:1990-1995(2003).
CC -!- SIMILARITY: Belongs to the UPF0154 family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AL935258; CAD64433.1; -.
CC HAMAP; MF_00363; -.
CC InterPro; IPR005359; UPF0154.
CC Pfam; PF03672; UPF0154; 1.
CC TRANSMEM 5 27 POTENTIAL.
SQ SEQUENCE 78 AA; 8814 MW; D609FADACD0B2BCC CRC64;

Query Match 80.5%; Score 33; DB 1; Length 78;
Best Local Similarity 66.7%; Pred. No. 19;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1 IMIGVLGV 9
Db 12 VWIGVLVL 20

RESULT 13
PTHB_ERWAM STANDARD; PRT; 333 AA.
AC O32522;

```

---

```

DT 15-DEC-1998 (Rel. 37, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE PTS system, glucitol/sorbitol-specific IIBC component (EIIBC-GUT)
DE (Glucitol/sorbitol-permease IIBC component) (Phosphotransferase enzyme
DE II, BC component) (EC 2.7.1.69) (EIIBC-GUT).
GS SRLE.
OS Erwinia amylovora.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Erwinia.
OX NCBI_TaxID=552;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=EA7/74;
RX MEDLINE=98098075; PubMed=9435786;
RA Aldridge P., Metzger M., Geider K.;
RT "Genetics of sorbitol metabolism in Erwinia amylovora and its
RT influence on bacterial virulence.";
RL Mol. Genet. 256:611-619(1997).
CC -!- FUNCTION: This is a component of the phosphoenolpyruvate-dependent
CC sugar phosphotransferase system (PTS), a major carbohydrate active
CC -transport system. The IICD domains contain the sugar binding site
CC and the transmembrane channel; the IIA domain contains the primary
CC phosphorylation site (the donor is phospho-HPr); IIA transfers its
CC phosphoryl group to the IIB domain which finally transfers it to
CC the sugar.
CC -!- CATALYTIC ACTIVITY: Protein N-phosphohistidine + sugar = protein
CC histidine + sugar phosphate.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein. Inner membrane.
CC -!- SIMILARITY: Contains 1 PTS EIIB domain.
CC -!- SIMILARITY: Contains 1 PTS EIIC domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; Y14603; CAAT74942.1; -.
CC InterPro; IPR004702; Sorb_phosph_enII.
CC Pfam; PF03612; EIIBC-GUT; 1.
CC TIGRFAMs; TIGR00825; EIIBC-GUT; 1.
CC Phosphotransferase system; Sugar transport; Transferase;
KW Phosphorylation; Transmembrane; Inner membrane.
FT DOMAIN 1 ? EIIB.
FT DOMAIN ? 333 EIIC.
FT TRANSMEM 160 180 POTENTIAL.
FT TRANSMEM 191 211 POTENTIAL.
FT TRANSMEM 220 240 POTENTIAL.
FT TRANSMEM 243 263 POTENTIAL.
FT TRANSMEM 271 291 POTENTIAL.
FT TRANSMEM 304 324 POTENTIAL.
SQ SEQUENCE 333 AA; 34292 MW; 6181206F04A61CAB CRC64;

Query Match 80.5%; Score 33; DB 1; Length 333;
Best Local Similarity 87.5%; Pred. No. 62;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 MIGVLGV 9
Db 253 VIGVLGV 260

RESULT 14
Y390_MYCGE STANDARD; PRT; 660 AA.
AC Q49430; Q49332; Q49356;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Hypothetical ATP-binding protein MG390.

```



RP SEQUENCE FROM N.A.



DR InterPro; IPR001902; Sulph\_transpt.  
DR Pfam; PF01740; STAS; 1.  
DR Pfam; PF00916; Sulfate transp; 1.  
DR TIGRFAMs; TIGR00815; sulP; 1.  
DR PROSITE; PS01130; SLC26A; 1.  
DR PROSITE; PS00801; STAS; 1.  
KW Transport; Symport; Sulfate transport; Transmembrane;  
Multigene family.  
FT DOMAIN 1 83 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 84 104 POTENTIAL.  
FT DOMAIN 105 108 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 109 129 POTENTIAL.  
FT DOMAIN 130 133 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 134 154 POTENTIAL.  
FT DOMAIN 155 161 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 162 182 POTENTIAL.  
FT DOMAIN 183 189 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 190 210 POTENTIAL.  
FT DOMAIN 211 241 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 242 262 POTENTIAL.  
FT DOMAIN 263 269 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 270 290 POTENTIAL.  
FT DOMAIN 291 318 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 319 339 POTENTIAL.  
FT DOMAIN 340 355 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 356 376 POTENTIAL.  
FT DOMAIN 377 392 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 393 413 POTENTIAL.  
FT DOMAIN 414 420 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 421 441 POTENTIAL.  
FT DOMAIN 442 459 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 460 480 POTENTIAL.  
FT DOMAIN 481 677 CYTOPLASMIC (POTENTIAL).  
FT DOMAIN 505 629 STAS.  
FT CONFLICT 7 22 MISSING (IN REF. 4).  
SQ SEQUENCE 677 AA; 74661 MW; 11C87626A781DB71 CRC64;

Query Match 80.5%; Score 33; DB 1; Length 677;  
Best Local Similarity 77.8%; Pred. No. 1.1e+02;  
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9  
DB 464 IEIGVLIGV 472

Search completed: August 6, 2004, 08:33:09  
Job time : 15 secs

This Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 6, 2004, 08:32:42 ; Search time 35 Seconds  
(without alignments)  
81.133 Million cell updates/sec

Title: US-09-458-302B-193  
Perfect score: 41  
Sequence: 1 IMIGVLGV 9

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

SPTREMBL\_25:\*

- 1: sp\_archaea:\*
- 2: sp\_bacteria:\*
- 3: sp\_fungi:\*
- 4: sp\_human:\*
- 5: sp\_invertebrate:\*
- 6: sp\_mammal:\*
- 7: sp\_mhc:\*
- 8: sp\_organelle:\*
- 9: sp\_phase:\*
- 10: sp\_plant:\*
- 11: sp\_rodent:\*
- 12: sp\_virus:\*
- 13: sp\_vertebrate:\*
- 14: sp\_unclassified:\*
- 15: sp\_rvirus:\*
- 16: sp\_bacteriap:\*
- 17: sp\_archaeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	41	100.0	702	4 Q8N4D0	Q8N4D0 homo sapien
2	38	92.7	75	17 Q9YF39	Q9YF39 aeropyrum p
3	37	90.2	121	8 Q9B9D6	Q9B9D6 cilix glauc
4	37	90.2	126	8 Q7YCU2	Q7YCU2 synanthedon
5	37	90.2	447	16 Q8ZQJ4	Q8ZQJ4 salmonella
6	37	90.2	447	16 Q8Z839	Q8Z839 salmonella
7	37	90.2	447	16 Q83T12	Q83T12 salmonella
8	36	87.8	125	8 Q7Y6W9	Q7Y6W9 synanthedon
9	36	87.8	125	8 Q7Y6W8	Q7Y6W8 synanthedon
10	36	87.8	346	13 Q7Z232	Q7Z232 brachydanio
11	36	87.8	378	11 Q9D400	Q9D400 mus musculu
12	36	87.8	539	16 Q8NNI8	Q8NNI8 corynebacte
13	36	87.8	553	10 Q9LYQ0	Q9LYQ0 arabidopsis
14	36	87.8	563	11 Q8C0X2	Q8C0X2 mus musculu
15	36	87.8	863	5 Q95VF8	Q95VF8 dictyosteli
16	36	87.8	893	5 Q9Y1Y3	Q9Y1Y3 ephydatia f

17	35	85.4	95	16	Q8UBX1	Q8ubx1 agrobacteri
18	35	85.4	104	8	Q34821	Q34821 ithomia sp.
19	35	85.4	104	8	Q34706	Q34706 heliconius
20	35	85.4	107	8	Q37413	Q37413 agraulis va
21	35	85.4	119	8	Q9B9D8	Q9B9D8 spodoptera
22	35	85.4	125	8	Q8SGJ6	Q8SGJ6 cyclophora
23	35	85.4	192	17	Q26661	Q26661 methanobact
24	35	85.4	232	8	Q94UT1	Q94ut1 araschnia l
25	35	85.4	315	8	Q7YHL4	Q7Yhl4 lepidopsoci
26	35	85.4	373	16	Q8FUF3	Q8fuf3 corynebacte
27	35	85.4	402	16	Q8RPT3	Q8rft3 fusobacteri
28	35	85.4	423	5	Q20396	Q20396 caenorhabdi
29	35	85.4	428	16	Q912U4	Q912u4 pseudomonas
30	35	85.4	563	16	Q8NLT6	Q8nlt6 corynebacte
31	35	85.4	614	16	Q7UUY6	Q7uuy6 rhodopirell
32	34	82.9	58	16	Q8YN92	Q8yn92 anabaena sp
33	34	82.9	94	8	Q37613	Q37613 phyciodes s
34	34	82.9	103	8	Q37456	Q37456 danaus plex
35	34	82.9	104	8	Q37692	Q37692 vanessa ata
36	34	82.9	104	8	Q37418	Q37418 battus phil
37	34	82.9	104	8	Q37537	Q37537 libytheana
38	34	82.9	104	8	Q37367	Q37367 anaea andri
39	34	82.9	104	8	Q37555	Q37555 macrosoma s
40	34	82.9	104	8	Q37609	Q37609 pontia prot
41	34	82.9	104	8	Q37467	Q37467 enodia port
42	34	82.9	104	8	Q37670	Q37670 speyeria at
43	34	82.9	120	8	Q9B9D9	Q9B9d9 agrotis seg
44	34	82.9	120	8	Q9B9D0	Q9B9d0 idaea stram
45	34	82.9	125	8	Q9B9C9	Q9B9c9 idaea avers

#### ALIGNMENTS

#### RESULT 1

Q8N4D0 PRELIMINARY; PRT; 702 AA.

ID Q8N4D0;  
AC Q8N4D0;  
DT 01-OCT-2002 (Tremblrel. 22, Created)  
DT 01-OCT-2002 (Tremblrel. 22, Last sequence update)  
DT 01-OCT-2003 (Tremblrel. 25, Last annotation update)  
DE Carcinoembryonic antigen-related cell adhesion molecule 5.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Colon, and Kidney;  
RA Strausberg R.;  
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC034671; AAH34671.1; -  
DR GO; GO:0003779; F:actin binding; IEA.  
DR InterPro; IPR001589; Actbind\_actnin.  
DR InterPro; IPR003599; IG.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003598; IG\_c2.  
DR Pfam; PF00047; igf\_6.  
DR SMART; SM00409; ig; 7.  
DR SMART; SM00408; IGC2; 6.  
DR PROSITE; PS00019; ACTININ\_1; 3.  
DR PROSITE; PS00835; IG LIKE; 6.  
KW Immunoglobulin domain.  
SQ SEQUENCE 702 AA; 76781 MW; 97CCFB7399A0B05A CRC64;

Query Match 100.0%; Score 41; DB 4; Length 702;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 IMIGVLGV 9

Db 691 IMIGVLGV 699

```
RESULT 2
Q9YF39 PRELIMINARY; PRT; 75 AA.
AC Q9YF39;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Hypothetical protein APES012.
GN APES012.
OS Aeropyrum pernix.
OC Archaea; Crenarchaeota; Thermoprotei; Desulfurococcales;
OC Desulfurococcaceae; Aeropyrum.
OX NCBI_TaxID=56636;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=K1;
RX MEDLINE=99310339; PubMed=10382966;
RA Kawarabayashi Y., Hino Y., Horikawa H., Yamazaki S., Haikawa Y.,
RA Jin-no K., Takahashi M., Sekine M., Baba S.-I., Ankaï A., Kosugi H.,
RA Hosoyama A., Fukui S., Nagai Y., Nishijima K., Makazawa H.,
RA Takamiya M., Masuda S., Funahashi T., Tanaka T., Kudoh Y.,
RA Yamazaki J., Kushida N., Oguchi A., Aoki K.-I., Kubota K.,
RA Nakamura Y., Nomura N., Sako Y., Kikuchi H.;
RT "Complete genome sequence of an aerobic hyper-thermophilic
RT crenarchaeon, Aeropyrum pernix K1.";
RL DNA Res. 6:83-101(1999).
DR EMBL; AP000059; BAA79357.1; -.
DR PIR; A72733; A72733.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 75 AA; 8155 MW; C3601D24F88A68D9 CRC64;

Query Match 92.7%; Score 38; DB 17; Length 75;
Best Local Similarity 66.7%; Pred. No. 17;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGVG 9
D 1 IMIGVLGVG 9
D 30 IMIGVLGI 38
D 30 IMIGVLGI 38

RESULT 3
Q9B9D6 PRELIMINARY; PRT; 121 AA.
AC Q9B9D6;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE NADH dehydrogenase subunit 1 (EC 1.6.5.3) (NADH-ubiquinone
DE oxidoreductase chain 1) (Fragment).
GN NDI.
OS Cilix glaucata.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Drepanoidea;
OC Drepanidae; Drepaninae; Cilix.
OX NCBI_TaxID=104441;
RN [1]
RP SEQUENCE FROM N.A.
RA Abraham D., Ryrholm N., Wittzell H., Scoble M.J., Holloway J.D.,
RA Lofstedt C.;
RT "Molecular phylogeny of the subfamilies in Geometridae (Geometroidea:
RT Lepidoptera)";
RL Mol. Phylogenet. Evol. 0:0-0(2001).
CC -I- CATALYTIC ACTIVITY: NADH + UBIQUINONE = NAD(+) + UBIQUINOL.
CC -I- SIMILARITY: BELONGS TO THE COMPLEX I SUBUNIT 1 FAMILY.
DR EMBL; AF178859; AAK00986.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0005739; C:mitochondrion; IEA.
DR GO; GO:0008137; F:NADH dehydrogenase (ubiquinone) activity; IEA.
DR GO; GO:0016491; F:oxidoreductase activity; IEA.
DR GO; GO:0006118; P:electron transport; IEA.
DR InterPro; IPR001694; Resp_NADH_dhl.
```

```
RT LT2.";
RL Nature 413:852-856(2001).
DR EMBL: AE008737; AAL19819.1; -.
DR InterPro: IPR007333; Sgat_Ulaa.
DR Pfam: PF04215; Sgat_Ulaa_1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 447 AA; 48656 MW; 886B4E3FA2601154 CRC64;

Query Match 90.2%; Score 37; DB 16; Length 447;
Best Local Similarity 77.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9
Db 24 ILIGILVGV 32

RESULT 6
Q82839 Q82839 PRELIMINARY; PRT; 447 AA.
AC Q82839;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Possible transport protein.
GN STY0917.
OS Salmonella typhi.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Salmonella.
OX NCBI_TaxID=601;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CT18;
RX MEDLINE=21534947; PubMed=11677608;
RA Parkhill J., Dougan G., James K.D., Thomson N.R., Pickard D., Wain J.,
RA Churcher C., Mungall K.L., Bentley S.D., Holden M.T.G., Sebahia M.,
RA Baker S., Basham D., Brooks K., Chillingworth T., Connor P.,
RA Cronin A., Davies P., Davies R.M., Dowd L., White N., Farrar J.,
RA Feltwell T., Hamlin N., Haque A., Hien T.T., Holroyd S., Jagels K.,
RA Krogh A., Larsen T.S., Leather S., Moule S., O'Gaora P., Parry C.,
RA Quail M., Rutherford K., Simmonds M., Skelton J., Stevens K.,
RA Whitehead S., Barrrell B.G.;
RA "Complete genome sequence of a multiple drug resistant Salmonella
RT enterica serovar Typhi CT18."
RL Nature 413:848-852(2001).
DR EMBL: AL627268; CAD05323.1; -.
DR InterPro: IPR007333; Sgat_Ulaa.
DR Pfam: PF04215; Sgat_Ulaa_1.
KW Complete proteome.
SQ SEQUENCE 447 AA; 48638 MW; AECB4B7D47640976 CRC64;

Query Match 90.2%; Score 37; DB 16; Length 447;
Best Local Similarity 77.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9
Db 24 ILIGILVGV 32

RESULT 7
Q83T12 Q83T12 PRELIMINARY; PRT; 447 AA.
AC Q83T12;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Possible transport protein.
GN T2012.
OS Salmonella typhi.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Salmonella.
OX NCBI_TaxID=601;
```

```
[1]
RN SEQUENCE FROM N.A.
RP STRAIN=Ty2 / ATCC 700931;
RX MEDLINE=22531367; PubMed=12644504;
RA Deng W., Liou S.-R., Plunkett G. III, Mayhew G.F., Rose D.J.,
RA Burland V., Kodoyianni V., Schwartz D.C., Blattner F.R.;
RT "Comparative genomics of Salmonella enterica serovar Typhi strains Ty2
RT and CT18."
RL J. Bacteriol. 185:2330-2337(2003).
DR EMBL: AE016840; AA069624.1; -.
DR InterPro: IPR007333; Sgat_Ulaa.
DR Pfam: PF04215; Sgat_Ulaa_1.
SQ SEQUENCE 447 AA; 48656 MW; 4BDA1A3D1362A3B0 CRC64;

Query Match 90.2%; Score 37; DB 16; Length 447;
Best Local Similarity 77.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9
Db 24 ILIGILVGV 32

RESULT 8
Q7Y6W9 Q7Y6W9 PRELIMINARY; PRT; 125 AA.
AC Q7Y6W9;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE NADH dehydrogenase subunit 1 (Fragment).
OS Synanthedon culiciformis (large red-belted clearwing).
OG Mitochondrion.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Sesiioidea;
OC Sesiidae; Sesiinae; Synanthedon.
OX NCBI_TaxID=233842;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AK3, AK11, and AK4;
RA Kallies A.;
RT "Phylogeny of sesiid Taxa."
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY304162; AAP84241.1; -.
DR EMBL: AY304163; AAP84242.1; -.
DR EMBL: AY304166; AAP84245.1; -.
KW Mitochondrion.
FT NON_TER 125
SQ SEQUENCE 125 AA; 14294 MW; 960B26BE1C96656E CRC64;

Query Match 87.8%; Score 36; DB 8; Length 125;
Best Local Similarity 66.7%; Pred. No. 63;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLVGV 9
Db 16 LMLGVILGV 24

RESULT 9
Q7Y6W8 Q7Y6W8 PRELIMINARY; PRT; 125 AA.
AC Q7Y6W8;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE NADH dehydrogenase subunit 1 (Fragment).
OS Synanthedon pamphyla.
OG Mitochondrion.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Sesiioidea;
OC Sesiidae; Sesiinae; Synanthedon.
OX NCBI_TaxID=233844;
```

```
[1]
RN  SEQUENCE FROM N.A.
RP  STRAIN=AK1, and AK8;
RC  Kallies A.;
RT  "Phylogeny of sessid Taxa.";
RL  Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR  ENBL; AY304164; AAP84243.1; -.
DR  ENBL; AY304165; AAP84244.1; -.
KW  Mitochondrion.
SQ  NON TER 125
SQ  SEQUENCE 125 AA; 14294 MW; 960B26BE1C96656E CRC64;

Query Match      87.8%; Score 36; DB 8; Length 125;
Best Local Similarity 66.7%; Pred. No. 63;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY  1 IMIGVLVGV 9
DB  16 LMLGVLLGV 24

RESULT 10
Q7Z232 PRELIMINARY; PRT; 346 AA.
AC  Q7Z232
DT  01-JUN-2003 (TrEMBLrel. 24, Created)
DT  01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT  01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE  SI:ZC12P8.3 (Novel protein similar to human 5-hydroxytryptamine
DE  (Serotonin) receptor 5A (HTR5A)).
GN  SI:ZC12P8.3.
OS  Brachydanio rerio (Zebrafish) (Danio rerio).
OC  Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC  Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC  Cyprinidae; Danio.
OX  NCBI_TaxID=7955;
RN  SEQUENCE FROM N.A.
RP  Corby N.;
RL  Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
DR  ENBL; AL772146; CAD61100.1; -.
DR  GO; GO:0016021; C:integral to membrane; IEA.
DR  GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR  GO; GO:0007186; P:G-protein coupled receptor protein signaln. .; IEA.
DR  InterPro; IPR000276; GPCR_Rhodpsn.
DR  Pfam; PF00001; 7cm1; 1.
DR  PRINTS; PR00237; GPCRHHODOPSN.
DR  PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR  PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
SQ  SEQUENCE 346 AA; 39412 MW; B554D1BC1E74413E CRC64;

Query Match      87.8%; Score 36; DB 13; Length 346;
Best Local Similarity 55.6%; Pred. No. 1.6e+02;
Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY  1 IMIGVLVGV 9
DB  274 LMVGILLGV 282

RESULT 11
Q9D400 PRELIMINARY; PRT; 378 AA.
AC  Q9D400;
DT  01-JUN-2001 (TrEMBLrel. 17, Created)
DT  01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT  01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE  4933425K02Rik protein.
GN  4933425K02Rik.
OS  Mus musculus (Mouse).
OC  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX  NCBI_TaxID=10090;
```

```
[1]
RN  SEQUENCE FROM N.A.
RP  STRAIN=C57BL/6J; TISSUE=Testis;
RC  MEDLINE=21085660; PubMed=11217851;
RA  Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA  Arawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA  Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yananaka I.,
RA  Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA  Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA  Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA  Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA  Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA  Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA  Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA  Lyons P., Marchionni L., Mashima J., Nikaido I., Pesole G., Quackenbush J.,
RA  Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA  Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA  Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA  Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA  Hayashizaki Y.;
RT  "Functional annotation of a full-length mouse cDNA collection.";
RL  Nature 409:685-690 (2001).
DR  ENBL; AK016917; BAB30495.1; -.
DR  MGD; MGI:1921696; 4933425K02Rik.
DR  GO; GO:0016021; C:integral to membrane; IEA.
DR  GO; GO:0015229; F:solute:hydrogen antiporter activity; IEA.
DR  GO; GO:0006885; P:regulation of pH; IEA.
DR  InterPro; IPR006153; Na_H_porter.
DR  Pfam; PF00999; Na H Exchanger; 1.
SQ  SEQUENCE 378 AA; 41808 MW; 2F3AA347A2DE6188 CRC64;

Query Match      87.8%; Score 36; DB 11; Length 378;
Best Local Similarity 66.7%; Pred. No. 1.7e+02;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY  1 IMIGVLVGV 9
DB  341 VLJGVLVGI 349

RESULT 12
Q8NN18 PRELIMINARY; PRT; 539 AA.
AC  Q8NN18;
DT  01-OCT-2002 (TrEMBLrel. 22, Created)
DT  01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT  01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE  Predicted permease.
GN  CGL2211.
OS  Corynebacterium glutamicum (Brevibacterium flavum).
OC  Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
OC  Corynebacterineae; Corynebacteriaceae; Corynebacterium.
OX  NCBI_TaxID=1718;
RN  SEQUENCE FROM N.A.
RP  STRAIN=ATCC 13032 / DSM 20300 / NCIB 10025;
RC  Nakagawa S.;
RL  Complete genomic sequence of Corynebacterium glutamicum ATCC 13032.;
RL  Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR  ENBL; AF005281; BAB99604.1; -.
DR  GO; GO:0008324; F:cation transporter activity; IEA.
DR  GO; GO:0006813; P:potassium ion transport; IEA.
DR  InterPro; IPR006037; TrkAC.
DR  InterPro; IPR006512; YidE_YbjL.
DR  Pfam; PF02680; TrkA-C; 1.
DR  TIGRFAMs; TIGR01625; YidE_YbjL_dupl; 2.
KW  Complete proteome.
SQ  SEQUENCE 539 AA; 57150 MW; EE6E907F6D29FD7B CRC64;

Query Match      87.8%; Score 36; DB 16; Length 539;
Best Local Similarity 77.8%; Pred. No. 2.4e+02;
```

```
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 IMIGVLGV 9
   :|||||:
Db 369 LMIGVLGV 377

RESULT 13
Q9LYQO PRELIMINARY; PRT; 553 AA.
AC Q9LYQO;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
GN T28J14.90.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsi.
OX NCBI_TaxID=3702;
RN [1]
RN SEQUENCE FROM N.A.
RP Bevan M., Murphy G., Ridley P., Hudson S., Bancroft I., Mewes H.W.,
RA Rudd S., Lemcke K., Mayer K.F.X.;
RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RN SEQUENCE FROM N.A.
RP EU Arabidopsis sequencing project;
RA Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.
RL EMBL; AL163652; CAB87271.1; -.
DR FIR; T48486; T48486.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0004672; F:protein kinase activity; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR GO; GO:0006468; P:protein amino acid phosphorylation; IEA.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR007090; LRR_plant.
DR InterPro; IPR000719; Prot_kinase.
DR Pfam; PF00560; LRR; 2.
DR Pfam; PF00069; pkinase; 1.
DR ProDom; PD000001; Prot_kinase; 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
KW Hypothetical protein; ATP-binding; Transferase.
SQ SEQUENCE 553 AA; 61666 MW; 83149DBFE099D39D CRC64;

Query Match 87.8%; Score 36; DB 10; Length 553;
Best Local Similarity 77.8%; Pred. No. 2.5e+02;
Matches 7; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9
   :|||||:
Db 232 IIVGLGV 240

RESULT 14
Q8COX2 PRELIMINARY; PRT; 565 AA.
AC Q8COX2;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Hypothetical glutamic acid-rich region/Na+/H+ exchanger containing
DE protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Testis;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
```

```
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RL Nature 420:563-573 (2002).
DR EMBL; AK029525; BAC26494.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0015299; F:solute:hydrogen antiporter activity; IEA.
DR GO; GO:0006885; P:regulation of pH; IEA.
DR InterPro; IPR006153; Na_H_porter.
DR Pfam; PF00999; Na_H_Exchange; 1.
KW Hypothetical protein.
SQ SEQUENCE 565 AA; 61957 MW; 7ECBC2E03DC90655 CRC64;

Query Match 87.8%; Score 36; DB 11; Length 565;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 IMIGVLGV 9
   :|||||:
Db 341 VLIGVLGV 349

RESULT 15
Q9SVF8 PRELIMINARY; PRT; 863 AA.
AC Q9SVF8;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Chloride channel protein ClcA.
GN CLCA.
OS Dictyostelium discoideum (Slime mold).
OC Eukaryota; Mycetozoa; Dictyosteliida; Dictyostelium.
OX NCBI_TaxID=44689;
RN [1]
RN SEQUENCE FROM N.A.
RP STRAIN=KAX3;
RT Wang C.W., Liu C.I., Chang W.T.;
RT "Molecular analyses and functional studies of chloride channel protein
RL Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF414428; AAL07438.1; -.
DR GO; GO:0016020; C:membrane; IEA.
DR GO; GO:0005247; F:voltage-gated chloride channel activity; IEA.
DR GO; GO:0006821; P:chloride transport; IEA.
DR InterPro; IPR000644; CBS domain.
DR InterPro; IPR001807; Cl-channel_volt.
DR InterPro; IPR006311; Tat.
DR Pfam; PF00571; CBS; 2.
DR Pfam; PF00654; voltage_CLC; 1.
DR PRINTS; PR00762; CLCHANNEL.
DR SMART; SM00116; CBS; 1.
DR TIGRPFAMs; TIGR01409; TAT_signal_seq; 1.
SQ SEQUENCE 863 AA; 97298 MW; 575CEE036AE0A435 CRC64;

Query Match 87.8%; Score 36; DB 5; Length 863;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2 MIGVLGV 9
   :|||||:
Db 133 MIGVLGV 140
```

Search completed: August 6, 2004, 08:35:00  
Job time : 37 secs

This Page Blank (uspio)